var title_f31_43_32432="Location of transobturator midurethral sling";
var content_f31_43_32432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Transobturator midurethral sling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32432=[""].join("\n");
var outline_f31_43_32432=null;
var title_f31_43_32433="Multiple bruises";
var content_f31_43_32433=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple bruises",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 503px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Stephen Ludwig, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32433=[""].join("\n");
var outline_f31_43_32433=null;
var title_f31_43_32434="Oral paracocci";
var content_f31_43_32434=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F69875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F69875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oral lesions in chronic paracoccidioidomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 251px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oral lesions in a patient with chronic paracoccidioidomycosis. A. Gingivostomatitis. B. Stomatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shikanai-Yasuda, MA, Queiroz Telles Filho, F, Mendes, RP, et al. Consenso em paracoccidioidomicose [Guidelines in paracoccidioidomycosis]. Revista da Sociedade Brasileira de Medicina Tropical 2006; 39:297-310. Copyright &copy;2006 Sociedade Brasileira de Medicina Tropical.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32434=[""].join("\n");
var outline_f31_43_32434=null;
var title_f31_43_32435="Rape2";
var content_f31_43_32435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Traumatic rape of child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note 3rd degree laceration which was repaired in layers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc R.&nbsp;Laufer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32435=[""].join("\n");
var outline_f31_43_32435=null;
var title_f31_43_32436="Phenol: Patient drug information";
var content_f31_43_32436=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Phenol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/14/27875?source=see_link\">",
"     see \"Phenol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Castellani Paint Modified [OTC];",
"     </li>",
"     <li>",
"      Cepastat&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Cepastat&reg; [OTC];",
"     </li>",
"     <li>",
"      Cheracol&reg; Spray [OTC];",
"     </li>",
"     <li>",
"      Chloraseptic&reg; Kids Sore Throat Spray [OTC];",
"     </li>",
"     <li>",
"      Chloraseptic&reg; Mouth Pain [OTC];",
"     </li>",
"     <li>",
"      Chloraseptic&reg; Sore Throat Gargle [OTC];",
"     </li>",
"     <li>",
"      Chloraseptic&reg; Sore Throat Spray [OTC];",
"     </li>",
"     <li>",
"      Pain-A-Lay&reg; [OTC];",
"     </li>",
"     <li>",
"      Phenaseptic [OTC];",
"     </li>",
"     <li>",
"      Phenol EZ&reg; [OTC];",
"     </li>",
"     <li>",
"      Ulcerease&reg; [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Formula 44&reg; Sore Throat [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F209038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      P &amp; S&trade; Liquid Phenol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease the pain caused by sore throat, skin irritation, and cold sores.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702726",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to phenol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care when a large part of the skin is involved or where there are open wounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain fingernails, hair, and skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect clothing and fabrics from staining.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Lozenge:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695691",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Suck oral lozenge. Do not chew, break, or crush it. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705481",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swish around for 15 seconds and then spit out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not swallow this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use. Do not wash your hands after use if putting this on your hand.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705558",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Spray:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spray affected part of the mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wait 15 seconds and then spit out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not swallow this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12093 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-52D7E7C181-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32436=[""].join("\n");
var outline_f31_43_32436=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209037\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209038\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011757\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011756\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011761\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011762\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011764\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011759\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011760\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011765\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011766\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/14/27875?source=related_link\">",
"      Phenol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_43_32437="Laryngeal cleft class";
var content_f31_43_32437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Classification of laryngotracheal clefts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 698px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based on the Benjamin classification. Benjamin, B, Inglis, A. Minor congenital laryngeal clefts: diagnosis and classification. Ann Otol Rhinol Laryngol 1989; 98:417.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32437=[""].join("\n");
var outline_f31_43_32437=null;
var title_f31_43_32438="Treatment and prognosis of brain abscess";
var content_f31_43_32438=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of brain abscess",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/43/32438/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/43/32438/contributors\">",
"     Frederick S Southwick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/43/32438/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/43/32438/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/43/32438/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/43/32438/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/43/32438/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain abscess is a focal collection within the brain parenchyma, which can arise as a complication of a variety of infections, trauma, or surgery. Successful treatment of a brain abscess requires a high index of suspicion for the infection, which can have subtle presentations, and frequently requires a combination of drainage and antimicrobial therapy. A summary of key steps in management is provided in the Table (",
"    <a class=\"graphic graphic_table graphicRef50098 \" href=\"mobipreview.htm?25/8/25740\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The treatment and prognosis of brain abscess will be presented here. The pathogenesis, clinical manifestations, and diagnosis of this disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38104?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of brain abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful management of a brain abscess usually requires a combination of antibiotics and surgical drainage for both diagnostic and therapeutic purposes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs can be chosen depending upon the likely origin of the abscess and the probable pathogen(s) involved. These antibiotics include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"       Penicillin G",
"      </a>",
"      covers most mouth flora including both aerobic and anaerobic streptococci. However, the emergence of penicillinase-producing anaerobes (eg, B. fragilis, Prevotella) is a potential limitation of penicillin therapy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      readily penetrates brain abscesses; intralesional concentrations have been found to be 40",
"      <span class=\"nowrap\">",
"       microgram/mL.",
"      </span>",
"      This drug has excellent bactericidal activity against many anaerobes but is not active against aerobic organisms including microaerophilic streptococci. Given the excellent intralesional concentrations and the high probability of anaerobes, many experts recommend administering this agent to most patients with brain abscess.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      covers most aerobic and microaerophilic streptococci (and can be used in place of penicillin) but also covers many Enterobacteriaceae as well, which can cause brain abscess particularly in association with chronic ear or sinus infections or following penetrating trauma.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"       Cefotaxime",
"      </a>",
"      provides similar coverage.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/5\">",
"       5",
"      </a>",
"      ] should be used when brain abscess complicates a neurosurgical procedure or in cases in which the abscess culture grows P. aeruginosa.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"       Oxacillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1608?source=see_link\">",
"       nafcillin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      should be included when brain abscess follows penetrating head trauma or craniotomy, or when S. aureus bacteremia is documented. Vancomycin should be particularly considered for post-neurosurgery patients, in hospital-associated infections, and in communities where community-associated methicillin-resistant S. aureus is common until culture and susceptibility results are available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aminoglycosides,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    , tetracyclines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and first-generation cephalosporins (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    ) should",
"    <strong>",
"     not",
"    </strong>",
"    be used to treat brain abscess because these drugs do not cross the blood brain barrier at high concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that the empiric antimicrobial regimen be based on the presumptive source of the abscess and Gram stain results if available.",
"   </p>",
"   <p>",
"    For patients with a brain abscess arising from an oral, otogenic, or sinus source (eg, chronic otitis or mastoiditis, where the site of abscess is usually the temporal lobe or cerebellum; or frontal or ethmoid sinusitis, where the site of abscess is usually the frontal lobe), we recommend treatment with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV as a loading dose, followed by 7.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every eight hours; not to exceed 4 g per day)",
"      <strong>",
"       PLUS",
"      </strong>",
"      &nbsp;",
"      <strong>",
"       either",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      (20 to 24 million units per day IV in six equally divided doses) for a suspected oral focus, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (2 g IV every 12 hours)",
"      <strong>",
"       OR",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      (2 g IV every four to six hours) for a suspected sinus or otogenic source.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with a brain abscess from hematogenous spread (eg, bacteremia or endocarditis with multiple abscesses in middle cerebral artery distribution), we recommend treatment with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily in two equally divided doses adjusted for renal function) for empiric coverage of methicillin-resistant Staphylococcus aureus. If susceptibility testing reveals methicillin-sensitive S. aureus, vancomycin should be replaced with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1608?source=see_link\">",
"       nafcillin",
"      </a>",
"      (2 g IV every four hours)",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      (2 g IV every four hours).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      , dosed as above, may be added for initial empiric coverage if the bacteriology is uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For brain abscess in postoperative neurosurgical patients, we recommend treatment with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily in two equally divided doses adjusted for renal function)",
"      <strong>",
"       PLUS",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      (2 g IV every eight hours),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      (2 g IV every eight hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      (1 g IV every eight hours). If susceptibility testing reveals methicillin-sensitive S. aureus, vancomycin should be replaced with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1608?source=see_link\">",
"       nafcillin",
"      </a>",
"      (2 g IV every four hours)",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      (2 g IV every four hours).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For brain abscess following penetrating trauma, we recommend treatment with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily in two equally divided doses adjusted for renal function)",
"      <strong>",
"       PLUS either",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (2 g IV every 12 hours)",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      (2 g IV every four to six hours). If susceptibility testing reveals methicillin-sensitive S. aureus, vancomycin should be replaced with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1608?source=see_link\">",
"       nafcillin",
"      </a>",
"      (2 g IV every four hours)",
"      <strong>",
"       or",
"      </strong>",
"      &nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      (2 g IV every four hours).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternative regimens for methicillin-resistant Staphylococcus aureus are discussed below. (See",
"    <a class=\"local\" href=\"#H108513601\">",
"     'MRSA'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Subsequent treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the etiologic agent(s) has been identified by culture, treatment regimens should be simplified and directed to that pathogen(s). Specific regimens for bacterial meningitis are discussed separately; similar antibiotic regimens can generally be used for bacterial meningitis and brain abscesses, although brain abscesses require a longer duration of therapy. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15306?source=see_link\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108513601\">",
"    <span class=\"h4\">",
"     MRSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given substantial rates of methicillin-resistant Staphylococcus aureus (MRSA) infections,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (30 to 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two or three divided doses IV if renal function is normal) should be used as initial therapy when S. aureus is suspected or proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. If susceptibility testing reveals methicillin-sensitive S. aureus, therapy should be changed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    (2 g IV every four hours) or&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    (2 g IV every four hours). If the organism is methicillin-resistant, vancomycin should be continued and dosed to achieve serum trough concentrations of 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    A significant drawback to vancomycin is its poor penetration into the cerebrospinal fluid (CSF) of approximately 1 and 5 percent with uninflamed and inflamed meninges, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    can be added to vancomycin at a dose of 600 mg orally once daily or 300 to 450 mg twice daily because it achieves bactericidal concentrations in the cerebrospinal fluid regardless of meningeal inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/6,7,11\">",
"     6,7,11",
"    </a>",
"    ], although there are few data to support this [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. &nbsp;",
"    <br/>",
"    <br/>",
"    Based upon case reports and case series of patients with central nervous system (CNS) infections caused by MRSA, alternatives to vancomycin include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    (600 mg IV or orally twice daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/15-18\">",
"     15-18",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    component IV every 8 to 12 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/7,19,20\">",
"     7,19,20",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    (6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV once daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Although there are insufficient data regarding the efficacy of these regimens for the treatment of CNS infections caused by MRSA, these agents are reasonable alternatives when vancomycin cannot be used or is ineffective. Further studies are needed to establish the benefit of these agents for the treatment of CNS infections. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15306?source=see_link&amp;anchor=H108515050#H108515050\">",
"     \"Treatment of bacterial meningitis caused by specific pathogens in adults\", section on 'Staphylococcus aureus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antibiotics for brain abscess is prolonged, usually four to eight weeks. The duration of therapy should be guided by follow-up assessment of clinical course and imaging studies; antibiotic therapy is continued until there is a good clinical response and resolution of the CT or MRI findings. Contrast enhancement at the site of the abscess may persist for several months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, this finding alone is not an indication for continued antibiotic treatment or for surgical exploration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurosurgeon needs to be contacted at the time of initial diagnosis of a brain abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/7\">",
"     7",
"    </a>",
"    ]. Needle aspiration and surgical excision have both been used to treat brain abscess, and are also required for diagnosis, prior to the initiation of antibiotic therapy if possible. An exception may be when a brain abscess occurs in the setting of bacteremia, in which case empiric antibiotic therapy is based upon the results of blood culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Needle aspiration is generally preferable to surgical excision since the neurologic sequelae are reduced. Needle aspiration is preferred for speech areas and regions of the sensory or motor cortex and in comatose patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Burr hole is placed and then needle aspiration is performed under CT or ultrasonography guidance. It is important that the aspirate be cultured for aerobes and anaerobes, fungi, and Mycobacterium tuberculosis. If the abscess fails to change in size or expands in diameter, it should be reaspirated.",
"   </p>",
"   <p>",
"    Reports have emphasized an improved outcome with stereotactic guidance to improve the precision of needle aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/24\">",
"     24",
"    </a>",
"    ]. As an example, in one series of 29 patients treated with this approach, only 2 new neurological deficits developed after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Under certain circumstances, drainage may be delayed or not required:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Early cerebritis without evidence of cerebral necrosis",
"     </li>",
"     <li>",
"      Abscesses located in vital regions of the brain or those inaccessible to aspiration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the decision is made not to drain immediately, follow-up with sequential CT or MRI is critical. There are no specific guidelines for timing of follow-up imaging. A repeat scan in 48 hours and at one week are typical, although any change in clinical status requires immediate repeat imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Surgical excision",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision is a more radical approach that generally results in greater neurologic deficits and now is infrequently performed. Excision may be the initial treatment of choice in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Traumatic brain abscesses (to remove bone chips and foreign material)",
"     </li>",
"     <li>",
"      Encapsulated fungal brain abscesses",
"     </li>",
"     <li>",
"      Multiloculated abscesses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the following are indications for excision after initial aspiration and drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No clinical improvement within one week",
"     </li>",
"     <li>",
"      Depressed sensorium",
"     </li>",
"     <li>",
"      Signs of increased intracranial pressure",
"     </li>",
"     <li>",
"      Progressive increase in the ring diameter of the abscess",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with multiloculated lesions are more likely to recur and may require a second operative procedure for cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The course of intravenous antibiotic therapy can be shortened to four weeks following excision compared with drainage. Excised lesions are less likely to relapse than lesions that have only been drained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids should be used when substantial mass effect can be demonstrated on imaging.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    is administered at a loading dose 10 mg IV followed by 4 mg every six hours; the drug should be discontinued as soon as possible.",
"   </p>",
"   <p>",
"    The addition of glucocorticoids has a number of disadvantages including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduction in contrast enhancement on CT scan",
"     </li>",
"     <li>",
"      Slowing of capsule formation",
"     </li>",
"     <li>",
"      Increasing the risk of ventricular rupture",
"     </li>",
"     <li>",
"      Decreasing the penetration of antibiotics into the abscess",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published mortality rates from brain abscess range from zero to 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. In a large retrospective series from France of 96 patients with brain abscess, there was a significant difference in the mortality rate from 1993 to 1999 compared to the period 1980 to 1992 (8 versus 30 percent); there was also a trend toward earlier diagnosis and improved neurologic function in the more recent time period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poor prognostic factors for recovery from a brain abscess include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rapid progression of the infection before hospitalization",
"     </li>",
"     <li>",
"      Severe mental status changes on admission",
"     </li>",
"     <li>",
"      Stupor or coma (60 to 100 percent mortality)",
"     </li>",
"     <li>",
"      Rupture into the ventricle (80 to 100 percent mortality)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neurologic sequelae, of which seizures are the most common, occur in 30 to 60 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32438/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients with frontal brain abscess are particularly vulnerable to recurrent seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Successful management of a brain abscess usually requires a combination of antibiotics and surgical drainage (",
"      <a class=\"graphic graphic_table graphicRef50098 \" href=\"mobipreview.htm?25/8/25740\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The neurosurgeon needs to be contacted at the time of initial diagnosis of a brain abscess. Surgical drainage generally is required for both diagnosis and treatment. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend empiric antimicrobial therapy for all patients with a presumptive brain abscess (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Antimicrobial therapy should be administered as soon as possible, although preferably after diagnostic aspiration. The empiric antibiotic regimen is based upon the presumptive source of the abscess and Gram stain results if available. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Empiric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the etiologic agent(s) has been identified by culture, we recommend treatment regimens be simplified and directed to that pathogen(s) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Subsequent treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treatment for at least four to eight weeks, guided by follow up assessment of clinical course and imaging studies for resolution of the CT or MRI findings (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest glucocorticoids be used only when substantial mass effect can be demonstrated on a scan and the mental status is significantly depressed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mortality from brain abscess ranges from zero to 30 percent. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prognosis and outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic sequelae, of which seizures are the most common, occur in 30 to 60 percent of patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prognosis and outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/1\">",
"      Mathisen GE, Johnson JP. Brain abscess. Clin Infect Dis 1997; 25:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/2\">",
"      Chun CH, Johnson JD, Hofstetter M, Raff MJ. Brain abscess. A study of 45 consecutive cases. Medicine (Baltimore) 1986; 65:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/3\">",
"      Cavuoglu H, Kaya RA, T&uuml;rkmenoglu ON, et al. Brain abscess: analysis of results in a series of 51 patients with a combined surgical and medical approach during an 11-year period. Neurosurg Focus 2008; 24:E9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/4\">",
"      Arlotti M, Grossi P, Pea F, et al. Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. Int J Infect Dis 2010; 14 Suppl 4:S79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/5\">",
"      Martin-Canal G, Saavedra A, Asensi JM, et al. Meropenem monotherapy is as effective as and safer than imipenem to treat brain abscesses. Int J Antimicrob Agents 2010; 35:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/6\">",
"      Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/7\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/8\">",
"      Pfausler B, Spiss H, Beer R, et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg 2003; 98:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/9\">",
"      Jorgenson L, Reiter PD, Freeman JE, et al. Vancomycin disposition and penetration into ventricular fluid of the central nervous system following intravenous therapy in patients with cerebrospinal devices. Pediatr Neurosurg 2007; 43:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/10\">",
"      Wang Q, Shi Z, Wang J, et al. Postoperatively administered vancomycin reaches therapeutic concentration in the cerebral spinal fluid of neurosurgical patients. Surg Neurol 2008; 69:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/11\">",
"      Nau R, Prange HW, Menck S, et al. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother 1992; 29:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/12\">",
"      Perlroth J, Kuo M, Tan J, et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008; 168:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/13\">",
"      von Specht M, Gardella N, Tagliaferri P, et al. Methicillin-resistant Staphylococcus aureus in community-acquired meningitis. Eur J Clin Microbiol Infect Dis 2006; 25:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/14\">",
"      Pintado V, Meseguer MA, Fort&uacute;n J, et al. Clinical study of 44 cases of Staphylococcus aureus meningitis. Eur J Clin Microbiol Infect Dis 2002; 21:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/15\">",
"      Kessler AT, Kourtis AP. Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid. Infection 2007; 35:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/16\">",
"      Naesens R, Ronsyn M, Druw&eacute; P, et al. Central nervous system invasion by community-acquired meticillin-resistant Staphylococcus aureus. J Med Microbiol 2009; 58:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/17\">",
"      Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 2007; 41:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/18\">",
"      Saito N, Aoki K, Sakurai T, et al. Linezolid treatment for intracranial abscesses caused by methicillin-resistant Staphylococcus aureus--two case reports. Neurol Med Chir (Tokyo) 2010; 50:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/19\">",
"      Levitz RE, Quintiliani R. Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med 1984; 100:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/20\">",
"      Vartzelis G, Theodoridou M, Daikos GL, et al. Brain abscesses complicating Staphylococcus aureus sepsis in a premature infant. Infection 2005; 33:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/21\">",
"      Lee DH, Palermo B, Chowdhury M. Successful treatment of methicillin-resistant staphylococcus aureus meningitis with daptomycin. Clin Infect Dis 2008; 47:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/22\">",
"      Wallace MR, Sander AW, Licitra C, et al. Methicillin-resistant Staphylococcus aureus meningitis successfully treated with daptomycin. Infect Dis Clin Pract 2009; 17:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/23\">",
"      Ratnaike TE, Das S, Gregson BA, Mendelow AD. A review of brain abscess surgical treatment--78 years: aspiration versus excision. World Neurosurg 2011; 76:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/24\">",
"      Duma CM, Kondziolka D, Lunsford LD. Image-guided stereotactic management of non-AIDS-related cerebral infection. Neurosurg Clin N Am 1992; 3:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/25\">",
"      Carpenter JL. Brain stem abscesses: cure with medical therapy, case report, and review. Clin Infect Dis 1994; 18:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/26\">",
"      Ng PY, Seow WT, Ong PL. Brain abscesses: review of 30 cases treated with surgery. Aust N Z J Surg 1995; 65:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/27\">",
"      Su TM, Lan CM, Tsai YD, et al. Multiloculated pyogenic brain abscess: experience in 25 patients. Neurosurgery 2008; 62 Suppl 2:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/28\">",
"      Mampalam TJ, Rosenblum ML. Trends in the management of bacterial brain abscesses: a review of 102 cases over 17 years. Neurosurgery 1988; 23:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/29\">",
"      Quartey GR, Johnston JA, Rozdilsky B. Decadron in the treatment of cerebral abscess. An experimental study. J Neurosurg 1976; 45:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/30\">",
"      Schliamser SE, B&auml;ckman K, Norrby SR. Intracranial abscesses in adults: an analysis of 54 consecutive cases. Scand J Infect Dis 1988; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/31\">",
"      Seydoux C, Francioli P. Bacterial brain abscesses: factors influencing mortality and sequelae. Clin Infect Dis 1992; 15:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/32\">",
"      Tattevin P, Bruneel F, Clair B, et al. Bacterial brain abscesses: a retrospective study of 94 patients admitted to an intensive care unit (1980 to 1999). Am J Med 2003; 115:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/33\">",
"      Yang SY, Zhao CS. Review of 140 patients with brain abscess. Surg Neurol 1993; 39:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32438/abstract/34\">",
"      Jansson AK, Enblad P, Sj&ouml;lin J. Efficacy and safety of cefotaxime in combination with metronidazole for empirical treatment of brain abscess in clinical practice: a retrospective study of 66 consecutive cases. Eur J Clin Microbiol Infect Dis 2004; 23:7.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1279 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32438=[""].join("\n");
var outline_f31_43_32438=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Subsequent treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H108513601\">",
"      MRSA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Surgical excision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROGNOSIS AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1279\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1279|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/8/25740\" title=\"table 1\">",
"      Management brain abscess",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38104?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of brain abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15306?source=related_link\">",
"      Treatment of bacterial meningitis caused by specific pathogens in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_43_32439="Preoperative assessment of hemostasis";
var content_f31_43_32439=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preoperative assessment of hemostasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/43/32439/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/43/32439/contributors\">",
"     Steven Coutre, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/43/32439/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/43/32439/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/43/32439/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/43/32439/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/43/32439/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perhaps one of the most important tasks that fall to the consultative hematologist is the preoperative assessment of hemostasis. The time-honored tools available to the hematologist include the clinical bleeding history, the physical examination, and a few select laboratory tests. Despite advances in clinical laboratory medicine and the advent of entirely new technologies, little has changed in the tests that are utilized for the assessment of bleeding risk. They remain remarkably effective in providing the information needed to evaluate the risk of bleeding in the surgical setting. The challenge remains to make sure that all patients at risk receive the proper evaluation so that bleeding complications are avoided.",
"   </p>",
"   <p>",
"    This topic review will discuss the general approach to the preoperative assessment of hemostasis. Guidance concerning specific problem areas is provided separately, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoperative medical evaluation of the healthy patient. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=see_link\">",
"       \"Preoperative medical evaluation of the healthy patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical risk in patients with liver disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12858?source=see_link\">",
"       \"Assessing surgical risk in patients with liver disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Performance of gastroenterologic procedures in patients with abnormal hemostasis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31959?source=see_link\">",
"       \"Endoscopic procedures in patients with disorders of hemostasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medical management of the dialysis patient undergoing surgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36601?source=see_link\">",
"       \"Medical management of the dialysis patient undergoing surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Management of anticoagulation before and after elective surgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=see_link\">",
"       \"Management of anticoagulation before and after elective surgery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE CLASSIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elegant review published by Dr. Samuel Rapaport in 1983 asked the question: \"Preoperative hemostatic evaluation: Which tests, if any?\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/1\">",
"     1",
"    </a>",
"    ]. The approach outlined in his concise review remains valid today.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     The clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical history remains the cornerstone of the preoperative assessment. However, four reasons have been cited why the history alone may be insufficient, suggesting a role for laboratory testing in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The forgetful physician &mdash; Simply put, this is a surgeon who does not take an adequate history. In our current medicolegal climate, this may be a very compelling argument for laboratory screening tests.",
"     </li>",
"     <li>",
"      The unreliable patient &mdash; A common example of the unreliable patient is one who claims to have no prior surgical history but neglects to mention wisdom teeth extractions or tonsillectomy. Both procedures are quite common, often occurring during the childhood years, and hence are often forgotten by the time of adulthood. Both operations are true challenges to hemostasis, since the oral cavity is rich in fibrinolytic substances.",
"      <br/>",
"      <br/>",
"      Alternatively, patients may recall these procedures but do not consider the bleeding they may have experienced as excessive. Having no basis for comparison, they may inadvertently overlook this complication. Other relevant items often overlooked include circumcision, childbirth and associated surgical procedures (eg, episiotomy), epistaxis, and the extent of menstrual blood losses.",
"     </li>",
"     <li>",
"      The unprovoked patient &mdash; A patient with an inherited bleeding disorder may not have experienced excessive bleeding in the past, especially if there has not been any prior surgery. In such patients the history will be uninformative unless there is a positive family history of bleeding.",
"     </li>",
"     <li>",
"      The acquired disorder &mdash; Patients with an acquired bleeding disorder may have no history of excessive surgical bleeding because their hemostatic defect is relatively recent in onset (eg, acquired von Willebrand disease).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Patient questionnaires",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient questionnaires are a logical way to obtain a bleeding history. One of the pitfalls, however, is the tendency of patients to over-report bleeding tendencies, such as easy bruising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/2\">",
"     2",
"    </a>",
"    ]. In such cases it can be quite difficult to rely solely on the history. The following is a questionnaire adapted and expanded from Dr. Rapaport's review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Do you experience excess bleeding in your mouth or frequent nosebleeds?",
"     </li>",
"     <li>",
"      Have you bled into a muscle or a joint? Have you ever had blood in your stool?",
"     </li>",
"     <li>",
"      Do you have profuse menstrual bleeding?",
"     </li>",
"     <li>",
"      Do you develop large bruises even in the absence of obvious injury? Have you bled excessively after small wounds?",
"     </li>",
"     <li>",
"      Have you had teeth extracted? How long did you bleed? Was the bleeding immediate or delayed?",
"     </li>",
"     <li>",
"      What operations have you undergone, including minor procedures such as skin biopsies or",
"      <span class=\"nowrap\">",
"       colonoscopy/bronchoscopy",
"      </span>",
"      with biopsies? Was there any bleeding, either immediate or delayed?",
"     </li>",
"     <li>",
"      Do you have other medical problems? Is there a history of hepatic, renal, or hematologic disease? Have you ever required a transfusion of whole blood, red blood cells, platelets, plasma, or blood clotting factors?",
"     </li>",
"     <li>",
"      What medications are you taking? Do you take anticoagulant medications? Have you taken",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or other pain relievers within the last 10 days? Do you take over-the-counter remedies, supplements, or alternative medicine (eg, herbal preparations)?",
"     </li>",
"     <li>",
"      Do any relatives have bleeding tendencies or experience excessive bleeding following surgery?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After reviewing the history, the physician should then be able to decide whether further laboratory information is required. In some cases the history does not suggest an underlying bleeding problem. If the patient has not had a sufficient challenge to hemostasis (eg, no prior surgical procedures) then the history may be uninformative and additional testing may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     The physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of findings on the physical examination are suggestive of a potential bleeding disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of petechiae (",
"      <a class=\"graphic graphic_picture graphicRef71480 \" href=\"mobipreview.htm?10/8/10372\">",
"       picture 1",
"      </a>",
"      ) or ecchymoses suggests thrombocytopenia or functionally deficient platelets (",
"      <a class=\"graphic graphic_table graphicRef77834 \" href=\"mobipreview.htm?2/43/2748\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/3/5178?source=see_link&amp;anchor=H6#H6\">",
"       \"Approach to the adult patient with a bleeding diathesis\", section on 'Disorders of platelets or blood vessels'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Telangiectasias may reflect underlying liver disease (eg, spider angiomas, often present on the trunk or face) (",
"      <a class=\"graphic graphic_picture graphicRef74047 \" href=\"mobipreview.htm?0/23/369\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23194?source=see_link\">",
"       \"Diagnostic approach to the patient with cirrhosis\"",
"      </a>",
"      .) Alternatively, they may represent hereditary hemorrhagic telangiectasia (characteristically present in the mouth and on the lips) (",
"      <a class=\"graphic graphic_picture graphicRef77416 \" href=\"mobipreview.htm?10/34/10786\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Evidence of past hemarthroses such as the presence of joint deformities in a patient with a positive bleeding history suggests severe factor deficiency (",
"      <a class=\"graphic graphic_table graphicRef77834 \" href=\"mobipreview.htm?2/43/2748\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1322?source=see_link&amp;anchor=H12#H12\">",
"       \"Clinical manifestations and diagnosis of hemophilia\", section on 'Late complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hematomas may also be due to factor deficiencies or inhibitors against a clotting factor (",
"      <a class=\"graphic graphic_table graphicRef77834 \" href=\"mobipreview.htm?2/43/2748\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Collagen-vascular disorders such as Ehlers-Danlos syndrome can be associated with prolonged bleeding due to an impairment in the structure of the blood vessels; other than increased capillary fragility, hematologic studies are usually normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/4\">",
"       4",
"      </a>",
"      ]. These patients have hyperelasticity of the skin and hyperextendable joints. Other disorders of blood vessel structure associated with clinical bleeding, which may have stigmata on physical examination, include scurvy and Cushing's syndrome (",
"      <a class=\"graphic graphic_picture graphicRef65564 \" href=\"mobipreview.htm?14/47/15103\">",
"       picture 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=see_link&amp;anchor=H4#H4\">",
"       \"Epidemiology and clinical manifestations of Cushing's syndrome\", section on 'Dermatologic manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LABORATORY TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early literature concerning the issue of preoperative assessment of hemostasis suggested the use of the prothrombin time (PT) and the activated partial thromboplastin time (aPTT) prior to surgery in order to detect those patients at risk for bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link\">",
"     \"Clinical use of coagulation tests\"",
"    </a>",
"    .) However, several retrospective studies suggest that routine laboratory testing is unnecessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study reviewed the records of 750 patients on a general surgery service and identified 139 (19 percent) patients whose history or physical exam suggested a bleeding tendency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/6\">",
"     6",
"    </a>",
"    ]. Twenty-five (18 percent) of these patients had an abnormal PTT or PT; 480 of the 611 patients with a negative history and physical examination had a PTT or PT measured. Only 13 (2.7 percent) had an abnormal result. Four were found to have normal results on repeat testing and the other nine underwent surgery without further evaluation. Only one of these patients had a bleeding complication, due to a bleeding arterial vessel. Given that 2.28 percent of individuals in a healthy population would be expected to have a prolonged PTT or PT (ie, a value more than two standard deviations above the mean), the prevalence of abnormal results of 2.7 percent in this study could be explained by random variation alone.",
"   </p>",
"   <p>",
"    A second study retrospectively reviewed 2000 patients admitted for elective surgery with a goal of identifying the frequency of unnecessary routine preoperative laboratory tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/7\">",
"     7",
"    </a>",
"    ]. The majority (77 percent) of the",
"    <span class=\"nowrap\">",
"     PTT/PT",
"    </span>",
"    determinations were not indicated based on patient histories. However, there was no analysis of the bleeding complications in either group, so it is difficult to determine whether the testing was valuable even in the group with a history suggestive of increased bleeding risk. Preoperative platelet counts were abnormal in only 2 of 407 patients screened.",
"   </p>",
"   <p>",
"    Prospective studies have also been performed in asymptomatic patients undergoing major surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. Bleeding time, platelet count, PT, and aPTT were measured in 111 patients on a general or thoracic surgery service [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/10\">",
"     10",
"    </a>",
"    ]. Only one patient had mild thrombocytopenia and eight had a prolonged aPTT. None experienced excessive bleeding, although the eight patients with the prolonged aPTT were found to have neither factor deficiencies nor a lupus anticoagulant as the explanation for their elevated aPTT. The same authors looked at this issue from a different perspective. They identified 49 out of 1872 patients who required perioperative red cell transfusion volumes which were larger than usual for the performed procedure. None of these patients had abnormal test results.",
"   </p>",
"   <p>",
"    One prospective study was quite comprehensive, evaluating the PT, aPTT, platelet count, and bleeding time in a multicenter study of 3242 consecutive patients undergoing general surgical procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/11\">",
"     11",
"    </a>",
"    ]. After screening patients by clinical history for increased bleeding risk, only one of 340 (0.3 percent) with a normal history but abnormal tests required treatment to correct the abnormality. In contrast, 26 of 172 (15 percent) with an abnormal history and abnormal tests required treatment. Overall surgical mortality was higher if patients had abnormal screening tests, but this was likely due to the greater severity of their underlying disease, since there was no difference in perioperative bleeding mortality.",
"   </p>",
"   <p>",
"    Mortality was significantly less in the 1951 patients with a normal history and normal tests compared with the 340 patients with a normal history but abnormal tests (0.87 percent versus 2.06 percent). The same was true when comparing the 779 patients with an abnormal history but normal tests with the 172 patients with an abnormal history and abnormal screening tests (2.18 percent versus 6.39 percent). These results suggest that laboratory screening is not necessary in patients undergoing general surgery unless the clinical history suggests a bleeding problem.",
"   </p>",
"   <p>",
"    Another prospective study looked at the impact of omitting preoperative laboratory testing in 3866 patients undergoing 3849 operations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/12\">",
"     12",
"    </a>",
"    ]. Following a protocol based on the patient's clinical status and type of surgery, the PT, aPTT, platelet count, and bleeding time were not ordered in 76 percent, 75 percent, 92 percent and 99 percent of patients, respectively, without any adverse effects.",
"   </p>",
"   <p>",
"    A prospective study evaluated the benefit of preoperative laboratory testing in predicting postoperative complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/13\">",
"     13",
"    </a>",
"    ]. Five hundred twenty patients undergoing elective general surgery were followed for perioperative complications. Measurement of the platelet count, PT, and aPTT were of no predictive value in this regard.",
"   </p>",
"   <p>",
"    One could argue that the majority of general surgical procedures are not associated with a high risk of bleeding and that the prevalence of bleeding disorders is low. Therefore, studies measuring perioperative morbidity and mortality due to bleeding would require huge numbers of patients. In addition, the majority of patients with bleeding disorders will be identified by the clinical history, calling into question the value of laboratory screening of asymptomatic individuals prior to surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/9,14-16\">",
"     9,14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bleeding time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the bleeding time (BT) has been widely used to predict surgical bleeding. Although it is a good test of platelet function, it is not necessarily a good screening test to predict bleeding risk. One review reported on 13 studies involving the bleeding time as a screening test; all but 2 were prospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/17\">",
"     17",
"    </a>",
"    ]. Seven studies involved cardiac surgery patients; the remainder included a variety of surgical patients. There was no correlation between the BT and surgical bleeding, whether assessed by chest tube drainage post cardiopulmonary bypass, transfusion requirement, or intraoperative blood loss. The authors pointed out that the skin bleeding time does not necessarily correlate with bleeding at other anatomical sites.",
"   </p>",
"   <p>",
"    A normal BT does not predict the safety of surgical procedures, nor does an abnormal BT predict excessive bleeding. As an example, a retrospective study found a 5 percent positive predictive value of the BT and a 95 percent negative predictive value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/3/5178?source=see_link&amp;anchor=H13#H13\">",
"     \"Approach to the adult patient with a bleeding diathesis\", section on 'Bleeding time'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SPECIFIC SURGICAL PROCEDURES AND THEIR BLEEDING RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are specific surgical procedures for which information is available concerning the value of preoperative laboratory screening. These common procedures include coronary bypass surgery, tonsillectomy, prostate surgery, and gynecologic oncology surgery. Because these patient populations are thought to have greater bleeding risk, more attention has been focused on the use of preoperative screening in these settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Coronary artery bypass surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of 897 consecutive adult cardiac surgical patients failed to demonstrate an association between post-operative bleeding as assessed by 16-hour mediastinal drainage and numerous laboratory tests of hemostasis, including the aPTT, PT, platelet count, activated clotting time, bleeding time, fibrinogen, and",
"    <span class=\"nowrap\">",
"     fibrin/fibrinogen",
"    </span>",
"    degradation products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/19\">",
"     19",
"    </a>",
"    ]. The first five tests were obtained preoperatively and all were measured post-bypass after adequate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    neutralization was documented. Although there was a statistically significant relationship between some of these variables and the amount of bleeding, there was broad scatter, making the predictive value of an individual test negligible. This was true even for patients with excessive post-bypass bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tonsillectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two prospective studies used preoperative screening for coagulation disorders in children undergoing tonsillectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The first measured the complete blood count, PT, aPTT, and BT in 1,603 children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/20\">",
"     20",
"    </a>",
"    ]. If an abnormality was found, the test was repeated one week later and if persistent abnormalities were found, further studies were undertaken. The 129 patients who reported prior perioperative bleeding or had laboratory abnormalities were assessed more thoroughly for a bleeding history with a standard questionnaire.",
"   </p>",
"   <p>",
"    Fourteen patients (11 percent) had a positive bleeding history. Fifteen patients had persistent laboratory abnormalities, including five with a lupus inhibitor, six with a non-lupus inhibitor, one with mild hemophilia A, one with von Willebrand disease, and two with prolonged aPTT of undetermined cause. These patients all received therapy to correct their hemostatic abnormality prior to surgery. Although history and screening tests had a high degree of specificity (0.86 and 0.99, respectively), in the final analysis they were insensitive (0.03 for both). The poor sensitivity and low prevalence of bleeding (2.3 percent) led to a very low positive predictive value (0.07) in predicting postoperative bleeding.",
"   </p>",
"   <p>",
"    The second study looked only at the predictive value of the bleeding history and measurement of the aPTT and PT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/21\">",
"     21",
"    </a>",
"    ]. Six of 96 patients had positive histories with possible von Willebrand disease in one patient, a lupus inhibitor in two, and normal laboratory tests in three. Fourteen of 90 patients (16 percent) with negative histories had prolongation of the aPTT, but only one had possible von Willebrand disease and did not bleed following surgery. None of the patients with positive questionnaires or prolonged aPTT bled after surgery; even histories suggestive of a mild bleeding disorder were not accurate in predicting postoperative bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Gynecologic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although elective gynecologic surgery is not associated with a high risk of bleeding, patients undergoing gynecologic surgery for malignancies may be at higher risk. A retrospective study looked at 351 patients on the gynecologic oncology service undergoing surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/22\">",
"     22",
"    </a>",
"    ]. Twelve (3.4 percent) had prolonged PT or aPTT, while 57 of 322 patients (18 percent) had elevation of fibrinogen and positive D-dimer. Of 322 patients, 188 had at least one abnormal test result. However, there were no perioperative deaths or re-explorations due to bleeding and only one post-operative hematoma, leading the authors to conclude that routine preoperative testing for coagulopathy was of little use clinically, despite the high prevalence of these abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prostate surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery of the prostate, for both benign and malignant disease is well known to be associated with a risk of significant bleeding as the urogenital system is rich in urokinase. Not only local fibrinolytic reactions, but also disseminated intravascular coagulation (DIC) have been associated with prostate surgery. Hence, there has been long-standing interest in the role of preoperative hematologic screening tests. One study measured the preoperative PT, aPTT, fibrinogen, and platelet count in 165 consecutive patients undergoing prostate surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/23\">",
"     23",
"    </a>",
"    ]. Benign prostatic hypertrophy (BPH) was present in 116 patients, adenocarcinoma in 45 patients, and both diagnoses in 4 patients. Two patients had thrombocytopenia with bone marrow examination showing metastatic disease; studies for the presence of DIC were normal and these two patients had uneventful prostatic biopsies. One patient with normal preoperative values developed DIC after biopsy, while three patients with BPH had normal screening tests but experienced bleeding due to local fibrinolysis. It could be concluded that the hematologic screening tests were not helpful in predicting bleeding complications, either due to faulty surgical hemostasis or hematologic problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recommended approach, balancing the information from the bleeding history, the physical examination, the inherent bleeding risk of the planned surgery, and the appropriate laboratory tests of hemostasis is found below. Each patient should be considered on an individual basis, with a strong emphasis on the clinical history and physical examination, as well as the risk of bleeding from a particular surgical procedure, before deciding whether",
"    <strong>",
"     any",
"    </strong>",
"    preoperative laboratory screening for coagulation disorders is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Routine screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of routine preoperative screening for adequacy of hemostasis depends, in part, on an evaluation of the risk of bleeding. This begins by defining the level of hemostatic risk for the proposed surgery, as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Low risk surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low risk surgical procedures have the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonvital organs are involved",
"     </li>",
"     <li>",
"      The surgical site is exposed (ie, not a closed biopsy procedure)",
"     </li>",
"     <li>",
"      There is a limited degree of surgical dissection",
"     </li>",
"     <li>",
"      Local hemostatic measures are likely to be effective",
"     </li>",
"     <li>",
"      The site does not have local fibrinolysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examples of low risk surgical procedures include lymph node biopsy, herniorrhaphy, and dental extractions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Moderate/high risk surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate or high risk surgical procedures have some or all of the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vital organs are involved, with deep or extensive dissection",
"     </li>",
"     <li>",
"      The site is associated with local fibrinolysis (eg, prostatic surgery, tonsillectomy, oral or nasal surgery)",
"     </li>",
"     <li>",
"      Local hemostatic measures are ineffective (eg, closed liver or kidney biopsy)",
"     </li>",
"     <li>",
"      The surgical procedure or the underlying condition is expected to induce a hemostatic defect (eg, cardiopulmonary bypass, brain injury, extensive malignancy)",
"     </li>",
"     <li>",
"      Bleeding complications are frequent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      are likely to compromise the surgical result",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examples of moderate and high risk surgical procedures, in addition to those listed immediately above, include laparotomy, thoracotomy, mastectomy, neurosurgical and ophthalmic procedures, as well as surgical procedures employed to stop bleeding. Most laparoscopic procedures would fall into this category as well (eg, arthroscopic orthopedic procedures, gynecologic laparoscopy, and laparoscopic cholecystectomy or splenectomy).",
"   </p>",
"   <p>",
"    For low risk surgical procedures, if the history and physical examination (see",
"    <a class=\"local\" href=\"#H2\">",
"     'The classic approach'",
"    </a>",
"    above) does not suggest the presence of a bleeding disorder, no additional laboratory testing is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/13,26-29\">",
"     13,26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the examination suggests the presence of a bleeding disorder, appropriate screening tests should be performed (ie, PT, aPTT, platelet count). Additional testing will likely be required to establish a diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link\">",
"     \"Clinical use of coagulation tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/3/5178?source=see_link\">",
"     \"Approach to the adult patient with a bleeding diathesis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H17\">",
"     'Medical and hematologic consultations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    This recommendation differs from the guidelines published by the Italian Society for Haemostasis and Thrombosis (SISET) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/30\">",
"     30",
"    </a>",
"    ]. Despite acknowledging that all their recommendations are of grade D, they recommend that the PT, aPTT, and platelet count should be performed routinely before surgery or invasive procedures (except diagnostic endoscopies) even in the case of a negative history of bleeding.",
"   </p>",
"   <p>",
"    For moderate and high risk surgical procedures, the history and physical examination should be supplemented with determination of the PT, aPTT, and platelet count. If the history and physical and screening laboratory tests are negative, no additional testing is required. Additional testing will likely be required to establish a diagnosis if the history and physical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the screening laboratory testing are abnormal (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Medical and hematologic consultations'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    A normal bleeding time (BT) does not predict the safety of surgical procedures, nor does an abnormal BT predict for excessive bleeding; its use in routine preoperative screening does not appear to be warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32439/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Medical and hematologic consultations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The situation is different if the surgeon has requested a medical or hematologic consultation to assess the possibility of bleeding, especially if the history and physical examination strongly suggest the presence of a bleeding disorder. Such situations are no longer \"routine\", and require a greater degree of individualized attention. Under these circumstances, we recommend the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the history and physical examination is not suggestive of the presence of a bleeding disorder, the following laboratory tests should be obtained: liver function studies, creatinine, complete blood count with white blood cell differential, platelet count, and review of the peripheral blood smear, prothrombin time, and activated partial thromboplastin time.",
"     </li>",
"     <li>",
"      If the history",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      physical examination is suggestive of a bleeding disorder, additional tests should be ordered based on the nature of the bleeding (",
"      <a class=\"graphic graphic_table graphicRef77834 \" href=\"mobipreview.htm?2/43/2748\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef79969 \" href=\"mobipreview.htm?42/45/43740\">",
"       table 2",
"      </a>",
"      ). At a minimum, this should include all of the tests listed immediately above. Other tests, such as specific factor assays, platelet function studies,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a workup for von Willebrand disease should be guided by clinical judgment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link\">",
"       \"Clinical use of coagulation tests\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/3/5178?source=see_link\">",
"       \"Approach to the adult patient with a bleeding diathesis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24794?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical presentation and diagnosis of von Willebrand disease\", section on 'Laboratory testing'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/59/23482?source=see_link&amp;anchor=H8#H8\">",
"       \"Platelet function testing\", section on 'Platelet aggregometry'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/59/23482?source=see_link&amp;anchor=H17#H17\">",
"       \"Platelet function testing\", section on 'The platelet function analyzer'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/1\">",
"      Rapaport SI. Preoperative hemostatic evaluation: which tests, if any? Blood 1983; 61:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/2\">",
"      Wahlberg T, Blomb&auml;ck M, Hall P, Axelsson G. Application of indicators, predictors and diagnostic indices in coagulation disorders. I. Evaluation of a self-administered questionnaire with binary questions. Methods Inf Med 1980; 19:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/3\">",
"      Laine C, Williams SV, Wilson JF. In the clinic. Preoperative evaluation. Ann Intern Med 2009; 151:ITC1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/4\">",
"      De Paepe A, Malfait F. Bleeding and bruising in patients with Ehlers-Danlos syndrome and other collagen vascular disorders. Br J Haematol 2004; 127:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/5\">",
"      Silver D. What Routine Preoperative Tests for Bleeding Tendencies?. JAMA 1976; 236:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/6\">",
"      Eisenberg JM, Clarke JR, Sussman SA. Prothrombin and partial thromboplastin times as preoperative screening tests. Arch Surg 1982; 117:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/7\">",
"      Kaplan EB, Sheiner LB, Boeckmann AJ, et al. The usefulness of preoperative laboratory screening. JAMA 1985; 253:3576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/8\">",
"      Segal JB, Dzik WH, Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/9\">",
"      Chee YL, Crawford JC, Watson HG, Greaves M. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology. Br J Haematol 2008; 140:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/10\">",
"      Macpherson CR, Jacobs P, Dent DM. Abnormal peri-operative haemorrhage in asymptomatic patients is not predicted by laboratory testing. S Afr Med J 1993; 83:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/11\">",
"      Houry S, Georgeac C, Hay JM, et al. A prospective multicenter evaluation of preoperative hemostatic screening tests. The French Associations for Surgical Research. Am J Surg 1995; 170:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/12\">",
"      Blery C, Charpak Y, Szatan M, et al. Evaluation of a protocol for selective ordering of preoperative tests. Lancet 1986; 1:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/13\">",
"      Velanovich V. The value of routine preoperative laboratory testing in predicting postoperative complications: a multivariate analysis. Surgery 1991; 109:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/14\">",
"      Rohrer MJ, Michelotti MC, Nahrwold DL. A prospective evaluation of the efficacy of preoperative coagulation testing. Ann Surg 1988; 208:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/15\">",
"      Munro J, Booth A, Nicholl J. Routine preoperative testing: a systematic review of the evidence. Health Technol Assess 1997; 1:i.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/16\">",
"      Wojtkowski TA, Rutledge JC, Matthews DC. The clinical impact of increased sensitivity PT and APTT coagulation assays. Am J Clin Pathol 1999; 112:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/17\">",
"      Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991; 77:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/18\">",
"      Gewirtz AS, Miller ML, Keys TF. The clinical usefulness of the preoperative bleeding time. Arch Pathol Lab Med 1996; 120:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/19\">",
"      Gravlee GP, Arora S, Lavender SW, et al. Predictive value of blood clotting tests in cardiac surgical patients. Ann Thorac Surg 1994; 58:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/20\">",
"      Burk CD, Miller L, Handler SD, Cohen AR. Preoperative history and coagulation screening in children undergoing tonsillectomy. Pediatrics 1992; 89:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/21\">",
"      Close HL, Kryzer TC, Nowlin JH, Alving BM. Hemostatic assessment of patients before tonsillectomy: a prospective study. Otolaryngol Head Neck Surg 1994; 111:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/22\">",
"      Myers ER, Clarke-Pearson DL, Olt GJ, et al. Preoperative coagulation testing on a gynecologic oncology service. Obstet Gynecol 1994; 83:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/23\">",
"      Rader ES. Hematologic screening tests in patients with operative prostatic disease. Urology 1978; 11:243.",
"     </a>",
"    </li>",
"    <li>",
"     Francis CW, Kaplan KL. Hematologic problems in the surgical patient: Bleeding and thrombosis. In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ, Shattil S, et al. (Eds), Churchill Livingstone, New York 2000. p.2381.",
"    </li>",
"    <li>",
"     Seligsohn U, Coller B. Classification, clinical manifestations and evaluation of disorders of hemostasis. In: Williams' Hematology, 6th ed, Beutler E, Lichtman MA, Coller BS, et al. (Eds), McGraw-Hill, New York 2001. p.1471.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/26\">",
"      Narr BJ, Warner ME, Schroeder DR, Warner MA. Outcomes of patients with no laboratory assessment before anesthesia and a surgical procedure. Mayo Clin Proc 1997; 72:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/27\">",
"      Velanovich V. Preoperative laboratory screening based on age, gender, and concomitant medical diseases. Surgery 1994; 115:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/28\">",
"      Wattsman TA, Davies RS. The utility of preoperative laboratory testing in general surgery patients for outpatient procedures. Am Surg 1997; 63:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/29\">",
"      Adams JG Jr, Weigelt JA, Poulos E. Usefulness of preoperative laboratory assessment of patients undergoing elective herniorrhaphy. Arch Surg 1992; 127:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32439/abstract/30\">",
"      Cosmi B, Alatri A, Cattaneo M, et al. Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 2009; 124:e6.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1315 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-2.133.93.82-84A455F99E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32439=[""].join("\n");
var outline_f31_43_32439=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE CLASSIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      The clinical history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Patient questionnaires",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      The physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LABORATORY TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bleeding time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SPECIFIC SURGICAL PROCEDURES AND THEIR BLEEDING RISKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Coronary artery bypass surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tonsillectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prostate surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Routine screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Low risk surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Moderate/high risk surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Medical and hematologic consultations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1315\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1315|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/8/10372\" title=\"picture 1\">",
"      Petechiae in immune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/23/369\" title=\"picture 2\">",
"      Spider angiomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/34/10786\" title=\"picture 3\">",
"      Mucosal telangiectasias in HHT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/47/15103\" title=\"picture 4\">",
"      Bruising in Cushings disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1315|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/43/2748\" title=\"table 1\">",
"      Features of bleeding disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/45/43740\" title=\"table 2\">",
"      Causes PT and PTT abnormalities",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/35/12858?source=related_link\">",
"      Assessing surgical risk in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/18/1322?source=related_link\">",
"      Clinical manifestations and diagnosis of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24794?source=related_link\">",
"      Clinical presentation and diagnosis of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22282?source=related_link\">",
"      Epidemiology and clinical manifestations of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36601?source=related_link\">",
"      Medical management of the dialysis patient undergoing surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_43_32440="Evaluation of wrist pain and injury in children and adolescents";
var content_f31_43_32440=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of wrist pain and injury in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/43/32440/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/43/32440/contributors\">",
"     D Scott Upton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/43/32440/contributors\">",
"     Joseph Chorley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/43/32440/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/43/32440/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/43/32440/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/43/32440/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/43/32440/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/43/32440/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries to the wrist are common in children, adolescents, and young adults. A thorough understanding of the anatomy of the growing wrist, common wrist injuries, and other causes of wrist pain are essential to accurate diagnosis and appropriate treatment.",
"   </p>",
"   <p>",
"    An overview of the relevant anatomy, epidemiology, and evaluation of wrist injuries in children and adolescents will be presented below. Causes of wrist pain and injury are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link\">",
"     \"Overview of acute wrist injuries in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38855?source=see_link\">",
"     \"Causes of chronic wrist pain in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wrist and hand are described in the anatomic position with the fifth digits medial and the palm facing anterior. \"Lateral\" and \"radial\" describe the thumb side; \"medial\" and \"ulnar\" describe the little finger side. The anterior aspect is \"palmar\" or \"volar\" and the posterior aspect is \"dorsal.\"",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bones &ndash; The wrist is formed by articulations between the radius, ulna, and the carpal bones. There are eight carpal bones distributed in proximal and distal rows (",
"      <a class=\"graphic graphic_figure graphicRef78359 \" href=\"mobipreview.htm?26/34/27172\">",
"       figure 1",
"      </a>",
"      ). The scaphoid (ie, navicular) bone provides a stabilizing link between the proximal and distal carpal bones. During development, the carpal ossification centers and the growth plates of the distal radius and ulna appear and fuse in a predictable stepwise fashion that is used to determine skeletal age (",
"      <a class=\"graphic graphic_table graphicRef60678 \" href=\"mobipreview.htm?31/43/32443\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Joints &ndash; The distal radioulnar joint (DRUJ) is a small, J-shaped, fluid-filled joint where the ulnar head articulates with the ulnar notch in the distal radius (",
"      <a class=\"graphic graphic_figure graphicRef53465 \" href=\"mobipreview.htm?28/11/28853\">",
"       figure 2",
"      </a>",
"      ). It serves as the main point for supination and pronation of the forearm.",
"      <br/>",
"      <br/>",
"      The articulation between the distal radius and the scaphoid and lunate bones forms the radiocarpal joint (",
"      <a class=\"graphic graphic_figure graphicRef53465 \" href=\"mobipreview.htm?28/11/28853\">",
"       figure 2",
"      </a>",
"      ). The radiocarpal joint and the midcarpal joint, which is between the proximal and distal rows of carpal bones, are responsible for the majority of wrist flexion and extension.",
"      <br/>",
"      <br/>",
"      There is no direct bony articulation between the distal ulna and the carpal bones; the ulnar side of the wrist is supported by the triangular fibrocartilage complex (TFCC), interposed between the distal ulna and triquetrum (",
"      <a class=\"graphic graphic_figure graphicRef63443 \" href=\"mobipreview.htm?15/39/15986\">",
"       figure 3",
"      </a>",
"      ). The TFCC is the major stabilizer of the DRUJ; it includes the triangular fibrocartilage, ulnar collateral ligament, dorsal and palmar radioulnar ligaments, ulnolunate and ulnotriquetral ligaments, and the extensor carpi ulnaris tendon sheath [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ligaments and capsule &ndash; The wrist is supported by a thin joint capsule, a thick complex of crisscrossing ligaments, and the fascia covering the flexor and extensor tendons (the retinaculum). The ligaments of the wrist are divided into two main categories: intrinsic and extrinsic. Intrinsic ligaments bind the carpal bones together; extrinsic ligaments bind the distal radius and ulna to the carpal bones, providing stability.",
"      <br/>",
"      <br/>",
"      The palmar radiocarpal, scapholunate, and lunotriquetral ligaments are the most clinically important (",
"      <a class=\"graphic graphic_figure graphicRef63301 \" href=\"mobipreview.htm?38/7/39030\">",
"       figure 4",
"      </a>",
"      ). The palmar radiocarpal ligaments ensure that the carpal bones move with the radius during supination and pronation. Disruption of the scapholunate and lunotriquetral ligaments can lead to chronic pain and instability.",
"     </li>",
"     <li>",
"      Muscles and tendons &ndash; The muscles of the wrist are divided into two major groups: palmar and dorsal. The palmar group includes the wrist and finger flexors and the forearm pronators. They are innervated by the median and ulnar nerves. The dorsal group includes the wrist and finger extensors and thumb extensors and abductors. They are innervated by the radial nerve.",
"      <br/>",
"      <br/>",
"      The tendon sheaths of the fifth flexor digitorum superficialis and profundus share a common sheath in the carpal tunnel that extends just distal to the wrist (",
"      <a class=\"graphic graphic_figure graphicRef53265 \" href=\"mobipreview.htm?18/45/19158\">",
"       figure 5",
"      </a>",
"      ). Thus, infections from the sheath of the 5th digit can extend to the wrist via direct communication with the common flexor sheath.",
"     </li>",
"     <li>",
"      Vessels &ndash; The ulnar and radial arteries, branches of the brachial artery, are the main arteries of the forearm. At the level of the wrist, each of these arteries contributes branches to form the superficial and deep palmar arches that supply the hand.",
"     </li>",
"     <li>",
"      Nerves &ndash; The wrist is innervated by the median, ulnar, and radial nerves (",
"      <a class=\"graphic graphic_table graphicRef53902 \" href=\"mobipreview.htm?24/11/24763\">",
"       table 2",
"      </a>",
"      ). The median nerve traverses the carpal tunnel, an elliptically shaped canal enclosed by the inelastic flexor retinaculum ventrally and the carpal bones dorsally (",
"      <a class=\"graphic graphic_figure graphicRef59856 \" href=\"mobipreview.htm?1/28/1477\">",
"       figure 6",
"      </a>",
"      ). In addition to the median nerve, eight deep and superficial flexor tendons and their sheaths, the flexor pollicis longus tendon and sheath, and occasionally the radial and ulnar palmar bursae or the median artery pass through the carpal tunnel (",
"      <a class=\"graphic graphic_figure graphicRef53265 \" href=\"mobipreview.htm?18/45/19158\">",
"       figure 5",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      The ulnar nerve traverses Guyon's canal, which is bordered by the palmar carpal ligament, the transverse retinacular ligament, the pisiform, and the hook of the hamate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Biomechanics &ndash; The four principal movements of the wrist are flexion, extension, pronation, and supination; the wrist can also be deviated ulnarly and radially.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Wrist flexion and extension are initiated at the base of the metacarpals where the flexor carpi radialis and ulnaris (the major wrist flexors) and the extensor carpi radialis and ulnaris (the major wrist extensors) insert. Seventy to 90 degrees of flexion occurs at the wrist. The radiocarpal joint accounts for approximately 60 percent of the motion and the midcarpal joint for approximately 30 to 40 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The radioulnar joint is responsible for pronation and supination.",
"     </li>",
"     <li>",
"      The wrist has about 30 to 40 degrees of ulnar and 15 to 30 degrees of radial deviation. Much of this motion is due to translation of the proximal and distal carpal rows, which slide in opposite directions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanisms of wrist injury can be divided into four major categories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    (1) Impact",
"   </p>",
"   <p>",
"    (2) Weightbearing",
"   </p>",
"   <p>",
"    (3) Twisting",
"   </p>",
"   <p>",
"    (4) Throwing or repetitive motion",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impact &ndash; Fall onto the wrist (the most common mechanism of acute injury) or direct impact from contact with a fellow player, ball, or other object (eg, puck, racquet).",
"      <br/>",
"      <br/>",
"      Impact injuries include fractures (distal forearm, scaphoid, triquetral, hook of hamate), Kienb&ouml;ck's disease, and injuries to the ligaments and capsule [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/3\">",
"       3",
"      </a>",
"      ]. Repetitive impact can lead to overuse injuries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link\">",
"       \"Overview of acute wrist injuries in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38855?source=see_link&amp;anchor=H2#H2\">",
"       \"Causes of chronic wrist pain in children and adolescents\", section on 'Overuse injuries'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Most falls occur with the wrist in an extended and pronated position. If the wrist was radially deviated at the time of the fall, scaphoid injuries are more likely; if the wrist was ulnarly deviated, ulnar styloid and TFCC injuries should be considered.",
"     </li>",
"     <li>",
"      Weightbearing &ndash; Weightbearing injuries occur most frequently in gymnasts, wrestlers, weight lifters, and rock-climbers. Weightbearing injuries include dorsal wrist impaction syndrome, distal radius physis stress syndrome, DRUJ dislocation, TFCC injury, ganglion cyst, carpal tunnel syndrome, and intersection syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38855?source=see_link\">",
"       \"Causes of chronic wrist pain in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Twisting &ndash; Forceful rotation of the wrist can occur in any sport. Twisting injuries affect joint stability, typically at the DRUJ.",
"     </li>",
"     <li>",
"      Throwing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other repetitive motion &ndash; Throwing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other repetitive motion is common among players of racquet, stick, and club sports; weight lifters; rowers; and gymnasts. Repetitive motions can lead to overuse injuries including tendonitis, distal physeal stress reaction, and neuropathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38855?source=see_link\">",
"       \"Causes of chronic wrist pain in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Traumatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traumatic causes of wrist pain in children include acute injuries (fractures, ligamentous injuries) and overuse injuries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link\">",
"     \"Overview of acute wrist injuries in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38855?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes of chronic wrist pain in children and adolescents\", section on 'Overuse injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When considering potential etiologies, it is helpful to consider whether the pain is acute (&lt;4 weeks) or",
"    <span class=\"nowrap\">",
"     subacute/chronic",
"    </span>",
"    (&ge;4 weeks), ulnar or radial, and dorsal or palmar (",
"    <a class=\"graphic graphic_table graphicRef57608 \" href=\"mobipreview.htm?26/8/26765\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63434 \" href=\"mobipreview.htm?40/36/41549\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nontraumatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontraumatic causes of wrist pain in children and adolescents include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteomyelitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20087?source=see_link\">",
"       \"Clinical features of hematogenous osteomyelitis in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33289?source=see_link\">",
"       \"Evaluation and diagnosis of hematogenous osteomyelitis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Septic arthritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/30/14826?source=see_link\">",
"       \"Bacterial arthritis: Clinical features and diagnosis in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Juvenile idiopathic arthritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21046?source=see_link\">",
"       \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24983?source=see_link\">",
"       \"Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/31/24056?source=see_link\">",
"       \"Pauciarticular onset juvenile idiopathic arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rickets. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=see_link\">",
"       \"Overview of rickets in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital anomalies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38855?source=see_link&amp;anchor=H21#H21\">",
"       \"Causes of chronic wrist pain in children and adolescents\", section on 'Congenital anomalies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Carpal tarsal osteolysis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38855?source=see_link&amp;anchor=H20#H20\">",
"       \"Causes of chronic wrist pain in children and adolescents\", section on 'Carpal tarsal osteolysis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important aspects of the history include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/2,8,9\">",
"     2,8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with injuries, what was the exact mechanism of injury and the location of the wrist during the traumatic force? (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Where is the pain? Causes of wrist pain can be categorized according to whether they are ulnar or radial, or dorsal or palmar (",
"      <a class=\"graphic graphic_table graphicRef57608 \" href=\"mobipreview.htm?26/8/26765\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef63434 \" href=\"mobipreview.htm?40/36/41549\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      How long has the pain been present? Was it preceded by an injury? Acute (&lt;4 weeks) and",
"      <span class=\"nowrap\">",
"       subacute/chronic",
"      </span>",
"      (&ge;4 weeks) wrist pain have differing etiologies (",
"      <a class=\"graphic graphic_table graphicRef57608 \" href=\"mobipreview.htm?26/8/26765\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef63434 \" href=\"mobipreview.htm?40/36/41549\">",
"       table 4",
"      </a>",
"      ). Chronic wrist pain following an injury is suspicious for carpal instability, whereas chronic bilateral wrist pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      swelling may be the presentation of arthritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38855?source=see_link\">",
"       \"Causes of chronic wrist pain in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      How intense is the pain? What makes it better? What makes it worse?",
"     </li>",
"     <li>",
"      Are there associated complaints: swelling, paresthesias in the hand, or muscle weakness in the forearm or hand, fever. Paresthesias",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      muscle weakness suggest neuropathy. Paresthesias in the median nerve distribution after acute trauma may indicate dislocation of the lunate into the carpal tunnel; paresthesias in the ulnar distribution after acute trauma may indicate fracture of the pisiform or hamate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/9\">",
"       9",
"      </a>",
"      ]. Fever may indicate acute infection (osteomyelitis or septic arthritis).",
"     </li>",
"     <li>",
"      Does the patient hear sounds in the wrist during specific movements?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A high-pitched snap may be present in extensor carpi ulnaris (ECU) tendon subluxations. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38855?source=see_link&amp;anchor=H3#H3\">",
"       \"Causes of chronic wrist pain in children and adolescents\", section on 'Tendon injuries'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medium-pitched clicks may be present in scapholunate instability. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link&amp;anchor=H15#H15\">",
"       \"Overview of acute wrist injuries in children and adolescents\", section on 'Scapholunate'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low-pitched clunks often are associated with midcarpal instability. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link&amp;anchor=H17#H17\">",
"       \"Overview of acute wrist injuries in children and adolescents\", section on 'Midcarpal'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Crepitus may be present in wrist tenosynovitis or intersection syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38855?source=see_link&amp;anchor=H3#H3\">",
"       \"Causes of chronic wrist pain in children and adolescents\", section on 'Tendon injuries'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      What is the training routine and intensity of training? Increasing the intensity of training too quickly increases the risk of overuse injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/6,10\">",
"       6,10",
"      </a>",
"      ]. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38855?source=see_link&amp;anchor=H2#H2\">",
"       \"Causes of chronic wrist pain in children and adolescents\", section on 'Overuse injuries'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important components of the examination of the child with complaints of wrist pain or injury include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inspection",
"     </li>",
"     <li>",
"      Neurovascular examination",
"     </li>",
"     <li>",
"      Palpation",
"     </li>",
"     <li>",
"      Measurement or estimation of grip strength",
"     </li>",
"     <li>",
"      Assessment of range of motion",
"     </li>",
"     <li>",
"      Provocative testing to assess the integrity of the supporting ligaments",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Findings should be compared with the",
"    <span class=\"nowrap\">",
"     uninjured/nonpainful",
"    </span>",
"    wrist. Patients with a traumatic injury and severe pain should be evaluated by radiograph following assessment of their neurovascular status. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wrist should be inspected for swelling, ganglion, and signs of trauma or inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neurovascular exam",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurovascular examination includes palpation of the radial and ulnar pulses, and assessment of motor and sensory function in the distribution of the radial, ulnar, and median nerves (",
"    <a class=\"graphic graphic_table graphicRef53902 \" href=\"mobipreview.htm?24/11/24763\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation of the affected area and determination of the point of maximal tenderness may aid diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dorsal palpation &ndash; The distal radius and ulna, radiocarpal joint, ECU tendon, extensor carpi radialis (ECR) tendon, lunate, and ulnar styloid can be palpated on the dorsal surface of the wrist (",
"      <a class=\"graphic graphic_figure graphicRef78359 \" href=\"mobipreview.htm?26/34/27172\">",
"       figure 1",
"      </a>",
"      ). The TFCC is best palpated in the hollow between the pisiform, the flexor carpi ulnaris, and the ulnar styloid on the ulnar border of the wrist.",
"      <br/>",
"      <br/>",
"      The junction of the distal radius, scaphoid, and lunate bones occurs directly under the intersection of the extensor tendon of the index finger and a line drawn perpendicular to the most distal aspect of the radius. Another useful landmark for dorsal palpation is Lister's tubercle, which lies in approximately the middle of the distal radius, aligned with the third metacarpal (",
"      <a class=\"graphic graphic_figure graphicRef78359 \" href=\"mobipreview.htm?26/34/27172\">",
"       figure 1",
"      </a>",
"      ). The lunate and capitate lie between the third metacarpal and Lister's tubercle.",
"      <br/>",
"      <br/>",
"      Mild tenderness at the radiocarpal joint line is consistent with a simple sprain, whereas more significant tenderness is consistent with a more severe injury, such as distal radius fracture. Focal tenderness along either the ECU or ECR is consistent with tendonitis. Focal tenderness distal to the ulnar styloid is consistent with TFCC injury. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link\">",
"       \"Overview of acute wrist injuries in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38855?source=see_link\">",
"       \"Causes of chronic wrist pain in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anatomic snuff box &ndash; The anatomic snuff box is comprised of the distal radial styloid proximally, the base of the thumb distally, the abductor pollicis longus (APL) and extensor pollicis brevis (EPB) radially, and, at the ulnar aspect, the extensor pollicis longus (EPL). The scaphoid bone forms the floor of the snuff box, and is best palpated with the wrist in ulnar deviation (",
"      <a class=\"graphic graphic_figure graphicRef56302 \" href=\"mobipreview.htm?41/25/42386\">",
"       figure 7",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Tenderness of the floor of the snuff box may be due to fracture, avascular necrosis, or arthritis of the scaphoid. Focal tenderness along the APL, EPB, and EPL, or at the radial styloid, over which the tendons cross, is consistent with De Quervain's tenosynovitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of acute wrist injuries in children and adolescents\", section on 'Scaphoid fractures'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/40/27270?source=see_link\">",
"       \"de Quervain's tenosynovitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ulnar snuff box &ndash; The ulnar snuff box is the sulcus distal to the ulnar head formed by the ECU and FCU. Tenderness in the ulnar snuff box is suggestive of lunotriquetral instability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Lunotriquetral'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link&amp;anchor=H16#H16\">",
"       \"Overview of acute wrist injuries in children and adolescents\", section on 'Lunotriquetral'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Palmar palpation &ndash; The scaphoid tuberosity, flexor carpi radialis (FCR) tendon, palmaris longus (PL) tendon, and radial pulse can be palpated in the radial palmar region (",
"      <a class=\"graphic graphic_figure graphicRef69097 \" href=\"mobipreview.htm?1/31/1527\">",
"       figure 8",
"      </a>",
"      ). The scaphoid tuberosity is palpated distal to the palmar aspect of the radial styloid. The FCR is felt just radial to the PL with the wrist in flexion; they run in the middle of the wrist in the same orientation and in approximate alignment with the middle finger.",
"      <br/>",
"      <br/>",
"      The pisiform, hook of the hamate, flexor carpi ulnaris (FCU), and ulnar pulse can be palpated in the ulnar palmar region (",
"      <a class=\"graphic graphic_figure graphicRef69097 \" href=\"mobipreview.htm?1/31/1527\">",
"       figure 8",
"      </a>",
"      ). The pisiform is the bony prominence at the base of the hypothenar eminence; the hook of the hamate lies just radial and distal to the pisiform. Focal pain over the hamate in patients with an appropriate history is consistent with a fracture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of acute wrist injuries in children and adolescents\", section on 'Hamate fractures'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Range of motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Range of motion for flexion, extension, pronation, supination, and ulnar and radial deviation should be assessed. The intact ability to pronate and supinate the wrist against resistance excludes pathology of the DRUJ and TFCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/14\">",
"     14",
"    </a>",
"    ]. Decreased range of motion may indicate fracture, ligamentous instability, and Kienb&ouml;ck's disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Integrity of ligaments",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Scapholunate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The scaphoid shift test is used to detect laxity of the scaphoid ligaments. With one hand, the examiner passively moves the patient's hand from a position of extension and ulnar deviation to one of flexion and radial deviation, while the thumb of the examiner's other hand maintains firm pressure on the palmar aspect of the scaphoid. The examiner then releases pressure on the scaphoid and, if laxity is present, the subluxed scaphoid will move back into alignment with a palpable \"clunk.\" The injured wrist should be compared with the uninjured wrist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of acute wrist injuries in children and adolescents\", section on 'Scapholunate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Lunotriquetral",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lunotriquetral shear (or ballottement) test is performed by stabilizing the lunate and moving the pisotriquetral mass back and forth past the lunate in the anterior and posterior direction. A positive test is increased movement and pain compared with the other side (",
"    <a class=\"graphic graphic_figure graphicRef70789 \" href=\"mobipreview.htm?19/37/20048\">",
"     figure 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of acute wrist injuries in children and adolescents\", section on 'Lunotriquetral'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another test is to apply lateral pressure to the triquetrum while the wrist is radially deviated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     DRUJ instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;The piano key test and the DRUJ compression test may be helpful in assessing DRUJ instability.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The piano key test is performed on a pronated wrist; it is positive if ballottement of the ulnar head in a palmar direction produces little resistance compared with the other side. Alternatively, the patient forcibly presses both palms into the examination table; exaggerated dorsal-palmar translation compared with the opposite side indicates DRUJ instability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the DRUJ compression test, the examiner compresses the radial and ulnar heads together and then rotates the forearm (",
"      <a class=\"graphic graphic_figure graphicRef78662 \" href=\"mobipreview.htm?4/61/5074\">",
"       figure 10",
"      </a>",
"      ). Pain with this maneuver is suggestive of DRUJ instability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     TFCC tears",
"    </span>",
"    &nbsp;&mdash;&nbsp;Provocative maneuvers for TFCC tears include the TFCC compression test, the supination lift test, and the press test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/4,13,15\">",
"     4,13,15",
"    </a>",
"    ]. Elicitation of ulnar pain with any of these maneuvers constitutes a positive test, suggestive of TFCC injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the TFCC compression test, the examiner applies axial compression to the ulnar side of the wrist during radial and ulnar deviation (",
"      <a class=\"graphic graphic_figure graphicRef50337 \" href=\"mobipreview.htm?42/0/43009\">",
"       figure 11",
"      </a>",
"      ). Point tenderness is in between the ulnar styloid and triquetrum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     CMC joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain with compression of the base of the thumb in the AP direction suggests the carpometacarpal (CMC) joint as the source of wrist pain (",
"    <a class=\"graphic graphic_picture graphicRef65989 \" href=\"mobipreview.htm?15/11/15551\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Additional maneuvers",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Scaphoid fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The scaphoid compression test (also called the axial grind test) is used in combination with palpation of the scaphoid in the anatomic snuff box to evaluate for scaphoid fractures. It is performed by holding the thumb and gradually pushing in toward the scaphoid along the longitudinal axis of the thumb metacarpal; the test is positive if this elicits pain over the palmar scaphoid tubercle. The scaphoid compression test is sensitive and moderately specific for scaphoid fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of acute wrist injuries in children and adolescents\", section on 'Scaphoid fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     de Quervain's",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic maneuvers for de Quervain tenosynovitis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/40/27270?source=see_link&amp;anchor=H3#H3\">",
"     \"de Quervain's tenosynovitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Carpal tunnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic maneuvers for carpal tunnel syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42230?source=see_link\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs are the initial imaging test of choice for patients with wrist injuries. They are a critical tool in the diagnosis of many acute wrist injuries (eg, fractures, dislocations). Other modalities (computed tomography, bone scan, arthrography, and magnetic resonance imaging) are more helpful in patients with chronic complaints and may be indicated for better visualization of specific pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain films of the wrist are indicated in patients with suspected fracture and should be obtained in any patient with a history of trauma and focal pain or tenderness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Routine views",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four views are usually obtained in the initial evaluation: anteroposterior (AP), lateral, scaphoid view in ulnar deviation, and 45&ordm; semi-pronated oblique.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anteroposterior &ndash; The anteroposterior (AP) view is usually the best for identifying carpal fractures (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75655 \" href=\"mobipreview.htm?12/45/13010\">",
"       image 1",
"      </a>",
"      ). Absence of the scaphoid fat stripe (a small linear or triangular collection of fat, distal to the radial styloid and parallel to the radial border of the scaphoid) is suggestive of acute bony or ligamentous injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/9,19\">",
"       9,19",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Ulnar variance, or the relationship between the lengths of the radius and ulna, should be assessed. Ulnar variance is positive if the ulna is longer than the radius and negative if the ulna is shorter than the radius [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/4\">",
"       4",
"      </a>",
"      ]. Positive ulnar variance is associated with a thinner TFCC, making it more prone to injury. Positive ulnar variance is also associated with lunotriquetral injury. Negative lunar variance is associated with scapholunate injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link\">",
"       \"Overview of acute wrist injuries in children and adolescents\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      On the AP view, carpal malalignment and ligamentous injury may be indicated by:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An increased distance between the carpal bones. In the normal wrist, the distances between the carpal bones on the AP radiograph are equivalent (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61652 \" href=\"mobipreview.htm?10/32/10767\">",
"       image 2",
"      </a>",
"      ). An increased distance (&gt;3 mm) is significant for displacement (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52517 \" href=\"mobipreview.htm?14/30/14816\">",
"       image 3",
"      </a>",
"      ). The increased distance is often better appreciated if the fist is clenched; clenched fist views may be necessary if the initial AP radiograph is unrevealing. These findings may be difficult to interpret in skeletally immature children because of eccentric ossification and the chondral nature of the carpus; MRI imaging may be more useful [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Disruption of Gilula's lines (three arcs connecting the proximal carpals that should form smooth curved lines, (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83269 \" href=\"mobipreview.htm?14/22/14691\">",
"       image 4",
"      </a>",
"      )) can signify carpal malalignment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lateral &ndash; On the lateral view, the alignment of the carpals, particularly the lunate, capitate, and scaphoid, should be noted (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78664 \" href=\"mobipreview.htm?9/13/9424\">",
"       image 5",
"      </a>",
"      ). Normally, the capitate and lunate should be bisected by a line along the long axis of the radius, and the scaphoid should form an angle with the lunate of about 45 to 60 degrees on the lateral (",
"      <a class=\"graphic graphic_figure graphicRef80973 \" href=\"mobipreview.htm?23/5/23637\">",
"       figure 12",
"      </a>",
"      ). If these relationships are not preserved, referral to a hand surgeon is indicated for evaluation of malalignment and carpal instability.",
"     </li>",
"     <li>",
"      Scaphoid view in ulnar deviation &ndash; The scaphoid view in ulnar deviation permits better visualization of scaphoid (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58484 \" href=\"mobipreview.htm?24/17/24863\">",
"       image 6",
"      </a>",
"      ). This view may need to be specifically requested as it is not included in the standard wrist series at many facilities.",
"     </li>",
"     <li>",
"      45 degrees semi-pronated oblique &ndash; The oblique view is best for looking at the trapeziotrapezoidal joint and for basilar joint arthritis. Oblique views also are helpful for looking at scaphoid fractures and fractures of the hook of the hamate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Additional views",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the routine series is not diagnostic, additional radiographs may be helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A scaphoid series, which includes six views.",
"     </li>",
"     <li>",
"      An instability series, which is taken with the fist clenched and the wrist in flexion, extension, and radial and ulnar deviation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A carpal tunnel view, which provides better visualization of the hook of the hamate, pisiform, and trapezium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Other imaging techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the subacute setting (four weeks to nine months) or the chronic setting (more than nine months), the differential diagnosis broadens from fracture, ligament sprains, and instabilities to TFCC injuries and other non-traumatic causes such as synovitis, AVN, and osteoarthritis (",
"    <a class=\"graphic graphic_table graphicRef63434 \" href=\"mobipreview.htm?40/36/41549\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32440/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38855?source=see_link\">",
"     \"Causes of chronic wrist pain in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone scan shows increased uptake in fractures that may not be evident on plain radiographs.",
"     </li>",
"     <li>",
"      CT scan is superior to MRI for detection of fractures and cortical bone processes.",
"     </li>",
"     <li>",
"      MRI is superior to CT for bone marrow pathology; osteonecrosis; synovial pathology; and visualization of the TFCC, ligaments, and soft tissues.",
"     </li>",
"     <li>",
"      Arthrography is used to demonstrate ligament tears (with leakage of contrast into different compartments).",
"     </li>",
"     <li>",
"      MRI with and without intra-articular contrast is becoming the diagnostic procedure of choice for most wrist injuries not detected on plain films.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/20/7491?source=see_link\">",
"       \"Patient information: Common wrist injuries (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanisms of wrist injury include impact (fall or direct impact), weightbearing, twisting, and throwing or repetitive motion. A fall on an outstretched hand is the most common mechanism for acute wrist injuries in children and adolescents. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When considering potential causes of wrist pain, it is helpful to consider whether the pain is acute (&lt;4 weeks) or",
"      <span class=\"nowrap\">",
"       subacute/chronic",
"      </span>",
"      (&ge;4 weeks), ulnar or radial, and dorsal or palmar (",
"      <a class=\"graphic graphic_table graphicRef57608 \" href=\"mobipreview.htm?26/8/26765\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef63434 \" href=\"mobipreview.htm?40/36/41549\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Important aspects of the history in children and adolescents include the mechanism of injury, characteristics of the pain (duration, location, exacerbating and relieving factors), associated findings (swelling, paresthesia, fever, sounds), and details of the training routine. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important aspects of the examination in children and adolescents with wrist pain include assessment of neurovascular status, palpation of the affected area, determination of the point of maximal tenderness, range of motion, grip strength, and assessment of the integrity of the ligaments. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain radiographs are the initial imaging test of choice for patients with wrist injuries. Four views are usually obtained in the initial evaluation: anteroposterior (AP), lateral, scaphoid view in ulnar deviation, and 45 degrees semi-pronated oblique. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Plain radiographs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computed tomography, bone scan, arthrography, and magnetic resonance imaging are more helpful in patients with chronic complaints and may be indicated for better visualization of specific pathology. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Other imaging techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/1\">",
"      STUART HC, PYLE SI, CORNONI J, REED RB. Onsets, completions and spans of ossification in the 29 bonegrowth centers of the hand and wrist. Pediatrics 1962; 29:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/2\">",
"      Nguyen DT, McCue FC 3rd, Urch SE. Evaluation of the injured wrist on the field and in the office. Clin Sports Med 1998; 17:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/3\">",
"      Werner SL, Plancher KD. Biomechanics of wrist injuries in sports. Clin Sports Med 1998; 17:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/4\">",
"      Parmelee-Peters K, Eathorne SW. The wrist: common injuries and management. Prim Care 2005; 32:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/5\">",
"      Mirabello SC, Loeb PE, Andrews JR. The wrist: field evaluation and treatment. Clin Sports Med 1992; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/6\">",
"      Gill TJ 4th, Micheli LJ. The immature athlete. Common injuries and overuse syndromes of the elbow and wrist. Clin Sports Med 1996; 15:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/7\">",
"      Amadio PC. Epidemiology of hand and wrist injuries in sports. Hand Clin 1990; 6:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/8\">",
"      Le TB, Hentz VR. Hand and wrist injuries in young athletes. Hand Clin 2000; 16:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/9\">",
"      Ritchie JV, Munter DW. Emergency department evaluation and treatment of wrist injuries. Emerg Med Clin North Am 1999; 17:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/10\">",
"      O'Neill DB, Micheli LJ. Overuse injuries in the young athlete. Clin Sports Med 1988; 7:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/11\">",
"      Daniels JM 2nd, Zook EG, Lynch JM. Hand and wrist injuries: Part I. Nonemergent evaluation. Am Fam Physician 2004; 69:1941.",
"     </a>",
"    </li>",
"    <li>",
"     Reid, DC. Sports Injury Assessment and Rehabilitation, Churchill Livingstone, New York 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/13\">",
"      Rettig AC. Athletic injuries of the wrist and hand. Part I: traumatic injuries of the wrist. Am J Sports Med 2003; 31:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/14\">",
"      Morgan WJ, Slowman LS. Acute hand and wrist injuries in athletes: evaluation and management. J Am Acad Orthop Surg 2001; 9:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/15\">",
"      Buterbaugh GA, Brown TR, Horn PC. Ulnar-sided wrist pain in athletes. Clin Sports Med 1998; 17:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/16\">",
"      Grover R. Clinical assessment of scaphoid injuries and the detection of fractures. J Hand Surg Br 1996; 21:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/17\">",
"      Esberger DA. What value the scaphoid compression test? J Hand Surg Br 1994; 19:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/18\">",
"      Chen SC. The scaphoid compression test. J Hand Surg Br 1989; 14:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/19\">",
"      Terry DW Jr, Ramin JE. The navicular fat stripe: a useful roentgen feature for evaluating wrist trauma. Am J Roentgenol Radium Ther Nucl Med 1975; 124:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/20\">",
"      Cohen MS. Ligamentous injuries of the wrist in the athlete. Clin Sports Med 1998; 17:533.",
"     </a>",
"    </li>",
"    <li>",
"     Waters PM. The upper limb. In: Lovell and Winter's Pediatric Orthopaedics, 6th, Morrissy RT, Weinstein SL.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.921.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32440/abstract/22\">",
"      International Wrist Investigators' Workshop Terminology Committee. Wrist: terminology and definitions. J Bone Joint Surg Am 2002; 84-A Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     Mann FA, Gilula LA. Post-traumatic wrist pain and instability: A radiographic approach to diagnosis. In: The Wrist and Its Disorders, Lichtman A.  (Ed), WB Saunders, Philadelphia 1999. p.91.",
"    </li>",
"    <li>",
"     Yin Y, Gilula LA. Imaging of the symptomatic wrist. In: The Wrist, Lippincott Williams and Wilkins, Philadelphia 2001. p.61.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6526 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32440=[""].join("\n");
var outline_f31_43_32440=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Traumatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nontraumatic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Inspection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neurovascular exam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Range of motion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Integrity of ligaments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Scapholunate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Lunotriquetral",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - DRUJ instability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - TFCC tears",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - CMC joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Additional maneuvers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Scaphoid fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - de Quervain's",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Carpal tunnel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Routine views",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Additional views",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Other imaging techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6526\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6526|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/45/13010\" title=\"diagnostic image 1\">",
"      Scaphoid fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/32/10767\" title=\"diagnostic image 2\">",
"      Normal wrist radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/30/14816\" title=\"diagnostic image 3\">",
"      Scapholunate dissociation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/22/14691\" title=\"diagnostic image 4\">",
"      Gilula lines wrist radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/13/9424\" title=\"diagnostic image 5\">",
"      Normal adult wrist lateral radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/17/24863\" title=\"diagnostic image 6\">",
"      Normal adult scaphoid radiograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6526|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/34/27172\" title=\"figure 1\">",
"      Anatomy wrist dorsal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/11/28853\" title=\"figure 2\">",
"      Wrist joints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/39/15986\" title=\"figure 3\">",
"      Anatomy of the triangular fibrocartilage complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/7/39030\" title=\"figure 4\">",
"      Wrist ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/45/19158\" title=\"figure 5\">",
"      Cross section of wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/28/1477\" title=\"figure 6\">",
"      Carpal tunnel syndrome structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/25/42386\" title=\"figure 7\">",
"      Anatomy wrist radial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/31/1527\" title=\"figure 8\">",
"      Anatomy of the volar aspect of the wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/37/20048\" title=\"figure 9\">",
"      Lunotriquetral shear test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/61/5074\" title=\"figure 10\">",
"      Distal radioulnar joint compression test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/0/43009\" title=\"figure 11\">",
"      Triangular fibrocartilage complex compression test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/5/23637\" title=\"figure 12\">",
"      Carpal bone angles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6526|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/11/15551\" title=\"picture 1\">",
"      Carpometacarpal compression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6526|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/43/32443\" title=\"table 1\">",
"      Carpal ossification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/11/24763\" title=\"table 2\">",
"      Elbow sensation strength",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/8/26765\" title=\"table 3\">",
"      Acute wrist injury children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/36/41549\" title=\"table 4\">",
"      Causes of chronic wrist injury in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/30/14826?source=related_link\">",
"      Bacterial arthritis: Clinical features and diagnosis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38855?source=related_link\">",
"      Causes of chronic wrist pain in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/39/20087?source=related_link\">",
"      Clinical features of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=related_link\">",
"      Overview of acute wrist injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/20/7491?source=related_link\">",
"      Patient information: Common wrist injuries (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24983?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/40/27270?source=related_link\">",
"      de Quervain's tenosynovitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_43_32441="Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis";
var content_f31_43_32441=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tension-type headache in adults: Pathophysiology, clinical features, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/43/32441/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/43/32441/contributors\">",
"     Frederick R Taylor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/43/32441/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/43/32441/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/43/32441/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/43/32441/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/43/32441/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tension-type headache (TTH) is the most prevalent headache in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/1\">",
"     1",
"    </a>",
"    ]. The typical presentation of a TTH attack is that of a mild to moderate intensity, bilateral, nonthrobbing headache without other associated features.",
"   </p>",
"   <p>",
"    Understanding the pathophysiology and clinical aspects of TTH is important for accurate diagnosis and optimum treatment. However, TTH is a relatively featureless headache, making it the least distinct of all the primary headache phenotypes. In addition, it is the least studied of all the primary headache disorders, despite having perhaps the highest total socioeconomic impact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the classification, pathophysiology, epidemiology, clinical features, and diagnosis of TTH in adults. Treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37079?source=see_link\">",
"     \"Tension-type headache in adults: Acute treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1433?source=see_link\">",
"     \"Tension-type headache in adults: Preventive treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tension-type headache in children is also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34744?source=see_link\">",
"     \"Tension-type headache in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three main subtypes of TTH (",
"    <a class=\"graphic graphic_table graphicRef79672 \" href=\"mobipreview.htm?42/32/43531\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infrequent episodic TTH, with headache episodes less than one day a month",
"     </li>",
"     <li>",
"      Frequent episodic TTH, with headache episodes 1 to 14 days a month",
"     </li>",
"     <li>",
"      Chronic TTH, with headaches 15 or more days a month",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This division is relevant for several reasons. The underlying pathophysiology, impact on quality of life, and therapy differ among the subtypes, with peripheral pain mechanisms having more importance in episodic TTH, and central mechanisms having greater importance in chronic TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/2\">",
"     2",
"    </a>",
"    ]. Acute symptomatic treatments are used for infrequent or low frequency episodic TTH, while prophylactic treatments are used for high frequency episodic TTH and chronic TTH. Therefore, a precise diagnosis should be established. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients who meet all but one of the criteria for the episodic subtypes of TTH and do not fulfill criteria for migraine without aura are considered to have probable episodic TTH. Patients who meet the criteria for chronic TTH and also meet criteria for medication overuse headache are considered to have probable chronic TTH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=see_link&amp;anchor=H8#H8\">",
"     \"Headache syndromes other than migraine\", section on 'Medication overuse headache'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Each of the subtypes of TTH is additionally classified as occurring with or without pericranial muscle tenderness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/1\">",
"     1",
"    </a>",
"    ]. However, there are no data showing that patients with or without pericranial muscle tenderness differ in terms of TTH pathophysiology or response to treatment.",
"   </p>",
"   <p>",
"    The term tension-type headache replaces previous terms such as stress or tension headache, muscle-contraction headache, psychomyogenic headache, and psychogenic headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/1\">",
"     1",
"    </a>",
"    ]. Tension headache was originally named for its suspected etiology (ie, excessive stress or tension leading to muscle contraction). Sustained contracture of pericranial muscles was long believed to be causative in TTH, although the concept is no longer considered valid. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathophysiology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of TTH is probably multifactorial, but the precise mechanisms are uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/3\">",
"     3",
"    </a>",
"    ]. Environment influences development of episodic TTH more than chronic TTH, while genetic factors appear to play an important role in development of chronic TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Given the wide variation in frequency and intensity in TTH, not only between individuals, but within individuals over time, it is likely that the underlying pain mechanisms in TTH are dynamic and vary from one individual to another, and potentially from one attack to another in the same individual.",
"   </p>",
"   <p>",
"    The current pathophysiologic model of TTH posits that peripheral activation or sensitization of myofascial nociceptors are most likely of major importance in episodic TTH, while sensitization of pain pathways in the central nervous system due to prolonged nociceptive stimuli from pericranial myofascial tissues seems to be responsible for the conversion of episodic to chronic TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/3,7-11\">",
"     3,7-11",
"    </a>",
"    ]. Thus, stimuli that are normally innocuous are misinterpreted as pain in chronic TTH. Continuous nociceptive input from peripheral myofascial structures may induce central sensitization. The increased nociceptive stimulation of supraspinal structures results in increased facilitation and decreased inhibition of pain transmission at the level of the spinal dorsal",
"    <span class=\"nowrap\">",
"     horn/trigeminal",
"    </span>",
"    nucleus, and in increased pericranial muscle activity. Measurements of pain tolerance thresholds and suprathreshold stimulation have shown presence of generalized hyperalgesia in patients with chronic TTH, while diffuse noxious inhibitory control (DNIC) function is reduced in chronic TTH. One voxel-based morphometric brain MRI imaging study showed loss of gray matter structures involved in pain processing in patients with chronic TTH, which correlated with increasing years of headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacologic studies have shown that tricyclic drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    and nitric oxide synthase inhibitors can reverse central sensitization and the chronicity of headache. Finally, low frequency electrical stimulation has been shown to rapidly reverse central sensitization and may be a new modality in treatment of chronic TTH and other chronic pain disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1433?source=see_link\">",
"     \"Tension-type headache in adults: Preventive treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Heightened sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heightened sensitivity of pain pathways in the central nervous system, and perhaps in the peripheral nervous system, is thought to play a critical role in the pathogenesis of TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/2,12,13\">",
"     2,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Central factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;General pain sensitivity in the central nervous system is increased in chronic TTH, whereas central pain processing seems to be normal in episodic TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/13\">",
"     13",
"    </a>",
"    ]. Decreased pain, thermal, and electrical thresholds reported in patients with chronic TTH probably represent a central misinterpretation of incoming signals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Increased excitability of the central nervous system generated by repetitive and sustained pericranial myofascial input may be responsible for the transformation of episodic TTH into the chronic form.",
"   </p>",
"   <p>",
"    Altered brainstem reflex findings have suggested the limbic-controlled descending pain systems may be abnormal in patients with chronic TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nitric oxide may play a key role in the pathophysiology of TTH, and novel treatments for TTH that apply the antinociceptive effect of nitric oxide synthase inhibitors are under study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/8\">",
"     8",
"    </a>",
"    ]. Compared with control subjects without headache, subjects with TTH (unlike those with migraine) have no significant difference in levels of serum N-acetyl-aspartate (a marker of neuronal dysfunction) or serum brain derived neurotropic factor (which interacts with calcitonin gene related peptide) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Peripheral factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Firm evidence for peripheral abnormalities in TTH is still lacking, but muscular factors may be important, especially in episodic TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. Compared with matched control subjects without headache, subjects with episodic TTH demonstrate increased numbers of active and latent trigger points, forward head posture, and lesser neck mobility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Increased muscle tenderness is the most pronounced and consistent finding in TTH patients and probably represents the activation of peripheral nociceptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/23\">",
"     23",
"    </a>",
"    ]. The intensity and frequency of TTH positively correlates with pericranial muscle tenderness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/3\">",
"     3",
"    </a>",
"    ]. Although the origin of muscle tenderness is unknown, nociceptors around blood vessels in striated muscle, tendon insertions, and fascia have been suggested as sources of the pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/2,13\">",
"     2,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As previously noted, sustained contracture of pericranial muscles was long believed to be causative in TTH, but this concept is no longer considered valid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to migraine, hereditary factors seem to play a minor role in the pathogenesis of episodic TTH. However, genetic factors may be more important in the development of chronic TTH than episodic TTH. These conclusions are supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Danish twin study found no significant difference in concordance rates for episodic TTH between monozygotic and dizygotic twin pairs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/4\">",
"       4",
"      </a>",
"      ], suggesting little if any role for genetic factors",
"     </li>",
"     <li>",
"      Another study found that first-degree relatives of probands with chronic TTH had more than a threefold increased risk of chronic TTH compared with the general population, suggesting that a genetic factor played a role [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Evidence from a genetic study employing complex segregation analysis suggests that chronic TTH has a multifactorial inheritance, whereas episodic TTH may be caused by multiple genes in combination with environmental factors, or may have no genetic component at all [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache is one of the most common reasons for neurologic consultation, and TTH is the most prevalent type of primary headache in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/24\">",
"     24",
"    </a>",
"    ]. In the population-based Danish twin registry, the one-year-period prevalence of TTH among 12- to 41-year-old subjects was 86 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/25\">",
"     25",
"    </a>",
"    ]. Furthermore, the prevalence of TTH may be increasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the overall prevalence of TTH is high, most patients with TTH have the infrequent episodic subtype, with headaches less than one day a month. Using the International Classification of Headache Disorders-2 (ICHD-2) criteria to classify TTH subtypes, the Danish twin registry found that the one-year-period prevalences of infrequent episodic TTH, frequent episodic TTH, and chronic TTH were 63.5, 21.6, and 0.9 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/25\">",
"     25",
"    </a>",
"    ]. An earlier population study from the United States found that the one-year prevalences of episodic and chronic TTH were 38.3 and 2.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women have a slightly higher prevalence of TTH than men, especially with regard to the frequent episodic and chronic subtypes of TTH. In a Danish population study, the lifetime prevalence of episodic TTH in men and women was 69 and 88 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/28\">",
"     28",
"    </a>",
"    ]. In another Danish population-based study that evaluated 40-year-old subjects, men were more likely than woman to have no TTH and infrequent episodic TTH, while women were more likely than men to have frequent episodic TTH and chronic TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/29\">",
"     29",
"    </a>",
"    ]. These differences were all statistically significant.",
"   </p>",
"   <p>",
"    Data regarding age dependence of TTH are limited. In a population-based study from the United States, the prevalence of episodic TTH peaked in the fourth decade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/27\">",
"     27",
"    </a>",
"    ]. A Danish study found a decreasing prevalence of TTH with increasing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/28\">",
"     28",
"    </a>",
"    ]. Other studies have shown that TTH continues to be a problem in older patients, occurring in 20 to 30 percent of those over 60 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/27,30,31\">",
"     27,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, limited data suggest that whites have a higher prevalence of TTH than blacks of either sex in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Societal impact",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high prevalence of TTH, the global burden of disability caused by TTH is greater than that caused by migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. This indicates that the overall cost of TTH may also be greater than that of migraine. In one population study, episodic TTH sufferers reported a mean of nine lost work days and five reduced-effectiveness days, while chronic TTH sufferers reported a mean of 27 lost work days and 20 reduced-effectiveness days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/27\">",
"     27",
"    </a>",
"    ]. The burden is particularly high for the minority who has substantial and complicating co-morbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/33\">",
"     33",
"    </a>",
"    ]. The impact is greatest on those with TTH who continue to suffer into their geriatric years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/27,30,31\">",
"     27,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While TTH is the most common form of headache, only a small percentage of TTH sufferers seek medical care because of this diagnosis, probably because most individuals with TTH have infrequent, mild headaches. In fact, some experts regard the infrequent episodic subtype of TTH not as a disease, but as a normal phenomenon that does not require medical attention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical presentation of a TTH attack is that of a mild to moderate intensity, bilateral, nonthrobbing headache without other associated features. Descriptions of TTH pain are characteristically nondescript: \"dull,\" \"pressure,\" \"head fullness\", \"head feels large,\" or, more descriptively, \"like a tight cap\", \"band-like,\" or a \"heavy weight on my head or shoulders.\"",
"   </p>",
"   <p>",
"    The pain in TTH may infrequently be unilateral or pulsating. In the Danish TTH population, a pulsating quality of pain with TTH was seldom or never present in 80 to 86 percent of the respondents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/28,35\">",
"     28,35",
"    </a>",
"    ]. In another Danish study of TTH, the head pain was unilateral in 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blood work, brain imaging with CT or MRI scans, and spinal fluid analyses are usually normal in patients with TTH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pericranial muscle tenderness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tenderness of pericranial myofascial tissues and number of myofascial trigger points are considerably increased in patients with TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/11\">",
"     11",
"    </a>",
"    ]. Muscle tenderness in the head, neck, or shoulders (ie, pericranial tenderness) is associated with both the intensity and the frequency of TTH attacks and is typically exacerbated during the headache experience. The presence or absence of pericranial muscle tenderness should be elicited from the history and confirmed on examination by manual palpation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Manual palpation is performed by applying firm pressure with the second and third finger and making small rotating movements on the pericranial muscles, including the frontal, temporal, masseter, pterygoid, sternocleidomastoid, splenius, and trapezius muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An in-vivo study in tender trapezius muscle in patients with chronic TTH during rest and static exercise provided evidence of normal interstitial levels of inflammatory mediators and metabolites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/39\">",
"     39",
"    </a>",
"    ]. This finding suggests that tender muscles are not sites of ongoing inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Precipitating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress and mental tension are reported to be the most common precipitants for TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/40\">",
"     40",
"    </a>",
"    ]. However, they are found at the same frequency in migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In a small study comparing primary headache types, head and neck movements were important trigger factors in patients with episodic TTH, while foods, hunger, and odor were significantly more common in patients with migraine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Can change in pain sensitivity of muscle be a risk factor? In a population-based study of subjects with TTH who were followed for 12 years, those who developed frequent episodic TTH had normal muscle tenderness at baseline but increased tenderness at follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In these subjects, the pain thresholds were normal both at baseline and at follow-up. This finding suggests that increased pain sensitivity is a consequence of frequent TTH rather than a precipitating risk factor, and lends support to central sensitization as an important mechanism for the chronification of TTH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Relationship with migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine may precipitate or aggravate TTH in patients who have both types of headache. In a population study that compared clinical characteristics of TTH, the one-year prevalence and male to female ratios of TTH were similar in patients with and without migraine. However, the frequency and duration of TTH attacks were greater in the migraineurs compared with nonmigraineurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/42,46\">",
"     42,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of TTH is based upon clinical impression. There are no diagnostic tests specific for TTH.",
"   </p>",
"   <p>",
"    The diagnosis of TTH is made when the patient's description of the attacks is consistent with the typical features of TTH, the diagnostic criteria below are fulfilled, and the general and neurologic examinations are normal, with the possible exceptions of increased tenderness of pericranial myofascial tissues and the presence of trigger points. However, it may be difficult to distinguish episodic TTH from mild forms of migraine (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Diagnostic challenges'",
"    </a>",
"    below). In addition, critical attention to the temporal pattern of headaches is necessary to distinguish TTH from secondary headaches due to extensive symptom overlap (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Secondary headaches'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    As already noted, infrequent episodic TTH is very unlikely to be a presenting chief complaint in clinical practice. Because of the association of TTH-like symptoms with secondary headaches, such as those due to medication overuse or structural brain lesions, we suggest that practitioners strongly consider the possibility of a secondary headache disorder when patients present for clinical care with presumed TTH. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Secondary headaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the International Classification of Headache Disorders-2 (ICHD-2), TTH is characterized by having at least two of the following four features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The location of the pain is bilateral in either the head or neck",
"     </li>",
"     <li>",
"      The quality of the pain is steady (eg, pressing or tightening) and nonthrobbing",
"     </li>",
"     <li>",
"      The intensity of the pain is mild to moderate",
"     </li>",
"     <li>",
"      There is no aggravation of the headache by normal physical activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These diagnostic criteria can be viewed as based more upon what TTH is",
"    <strong>",
"     not",
"    </strong>",
"    : localized, throbbing, severe, or aggravated by activity. In addition, there must be at least 10 headache episodes fulfilling all other ICHD-2 criteria (",
"    <a class=\"graphic graphic_table graphicRef79672 \" href=\"mobipreview.htm?42/32/43531\">",
"     table 1",
"    </a>",
"    ), which include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The duration of pain is between 30 minutes to seven days",
"     </li>",
"     <li>",
"      The headache is not attributable to another disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ICHD criteria were designed to distinguish between TTH, migraine, and cluster headache. There are no auras with TTH, whether visual, language, sensory, motor, or coordination. Similarly, other features typically associated with migraine headache, such as nausea, vomiting, or sensitivity to light and noise, are not features of episodic TTH. However, the presence of photophobia or phonophobia (but not both) does not exclude the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/47\">",
"     47",
"    </a>",
"    ], nor does the presence of anorexia. There is an exception for chronic TTH that allows mild nausea as long as there is no photophobia or phonophobia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/47\">",
"     47",
"    </a>",
"    ]. The proportion of TTH associated with cranial autonomic features is currently unknown, but these are uncommon accompaniments in the author's experience.",
"   </p>",
"   <p>",
"    Further complete TTH classification requires subdividing by frequency of attacks and by determining pericranial muscle tenderness using manual palpation. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Classification'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Pericranial muscle tenderness'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When a patient has headaches that meet all but one of the TTH criteria, the practitioner must also consider whether criteria are met for migraine or probable migraine, and if not, the attacks can be classified as probable TTH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to neuroimaging in adult patients with headache is briefly reviewed here and discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation of headache in adults\", section on 'Danger signs on history'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation of headache in adults\", section on 'Indications for imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neuroimaging is not necessary in most patients with primary headaches, including those with TTH, who have a stable headache pattern for over six months and a normal neurologic examination. However, brain imaging should be considered in patients with nonacute headache who have any of the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An unexplained abnormal finding on neurologic examination",
"     </li>",
"     <li>",
"      Atypical headache features or headaches that do not fulfill the strict definition of a primary headache disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with sudden severe \"thunderclap\" headache also need neuroimaging to exclude serious conditions such as subarachnoid hemorrhage, cervical artery dissection, cerebral venous thrombosis, and others. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12601?source=see_link\">",
"     \"Thunderclap headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7594?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of cerebral venous thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Brain MRI with and without contrast is the test of choice for most patients when neuroimaging is warranted. However, head CT is more expeditious for evaluating those suspected of having acute intracranial hemorrhage.",
"   </p>",
"   <p>",
"    No other diagnostic tests are typically necessary in patients with \"garden-variety\" TTH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CHALLENGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic challenges occur in the evaluation of suspected TTH when there are atypical or missing features, when features overlap with other types of headaches, and when patients fail to report all symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Episodic tension-type headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the clinic, patients with a stable pattern of episodic, disabling headache and a normal physical examination should be considered to have migraine in the absence of contradictory evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/48\">",
"     48",
"    </a>",
"    ]. This hypothesis was validated by the Landmark study, which evaluated 1203 patients visiting a primary practitioner with a complaint of episodic headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/49\">",
"     49",
"    </a>",
"    ]. The subjects then recorded their next six headaches in diaries, and each headache was strictly classified according to the original 1988 International Classification of Headache Disorders (ICHD) criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/50\">",
"     50",
"    </a>",
"    ]. Overall, ICHD-defined migraine was present in 94 percent of the subjects (including 76 percent with migraine and 18 percent with probable migraine), while TTH, by definition episodic, was present in 3 percent.",
"   </p>",
"   <p>",
"    Diagnostic challenges occur when patients underreport symptoms by poorly describing them (typically underreporting migraine symptomatology) or when TTH-like headaches are more severe than typical TTH and associated with photophobia or phonophobia. In the Spectrum study, 32 percent of patients with an initial diagnosis of episodic TTH were diagnosed with migraine or probable migraine when headache diaries were reviewed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/51\">",
"     51",
"    </a>",
"    ]. Those TTH sufferers reclassified as migraineurs responded to triptans in the study, while episodic TTH sufferers not meeting criteria for migraine responded at placebo rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The results provide further support for the notion that patients with disabling episodic headache are more likely to suffer migraine than TTH.",
"   </p>",
"   <p>",
"    Distinguishing episodic TTH from migraine without aura may be difficult. As an example, the diagnosis of probable TTH can be made according to the ICHD-2 classification in a patient with a unilateral, severe, nonthrobbing headache that is not aggravated by normal physical activity and has no associated symptoms. This same individual also meets ICHD-2 criteria for probable migraine. In such cases, the ICHD-2 recommends that all other available information should be used to decide which of the alternative diagnoses are more likely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/47\">",
"     47",
"    </a>",
"    ]. This information may include patient age, gender, longitudinal headache history (especially regarding how the headache started), family history, the effect of drugs, whether headaches are related to menses, and a range of other features. Fulfillment of all diagnostic criteria for any headache disorder (eg, TTH or any of its subtypes) always trumps fulfillment of criteria for any \"probable\" diagnostic category (eg, probable migraine) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, throbbing or pulsating pain may infrequently occur with TTH, presumably when the pain is most intense [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/35\">",
"     35",
"    </a>",
"    ]. Thus, another possible presentation of headache that meets criteria for both TTH and migraine is that of a unilateral throbbing headache of mild to moderate intensity without aggravation by normal physical activity and without associated features. Nevertheless, one should be wary of classifying such a headache as TTH rather than probable migraine, since underreporting of migraine symptoms is a common problem. Descriptive reports of a series of headaches that record all details of each episode are warranted before being definitive about a primary TTH diagnosis in clinical practice.",
"   </p>",
"   <p>",
"    Other headaches that may cause diagnostic confusion with episodic TTH include cervicogenic headache and sinus headache. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Secondary headaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chronic tension-type headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;The challenges for a diagnosis of chronic TTH diagnosis are rather limited and fairly straightforward compared with episodic TTH. Typically, chronic TTH must be differentiated from other primary chronic daily headaches of long duration and, infrequently, from secondary headache disorders. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Secondary headaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The chronic daily headache disorders as a group are not addressed by the ICHD-2; rather, the classification of chronic daily headache as a form of headache is based upon criteria proposed by Silberstein and Lipton (SL criteria) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. In this paradigm, chronic TTH is classified under chronic daily headache, long duration subtype (at least four hours a day) (",
"    <a class=\"graphic graphic_table graphicRef52077 \" href=\"mobipreview.htm?20/23/20859\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    New daily persistent headache and hemicrania continua are distinct headache syndromes, and if the patient with chronic daily headache does not have a sudden onset of persistent headache or strictly unilateral pain, then the main diagnostic classification involves transformed or chronic migraine. One of three situations pertains:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis is transformed or chronic migraine if there are eight or more days a month of migraine headache or migraine-specific acute medication use (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      or triptans)",
"     </li>",
"     <li>",
"      The diagnosis is pure chronic TTH if all headache days fulfill criteria for chronic TTH",
"     </li>",
"     <li>",
"      The diagnosis is chronic TTH associated with episodic migraine if there are fewer than eight days a month of migraine headache or migraine-specific acute medication use",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Secondary headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary headaches may present diagnostic challenges for both episodic and chronic TTH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Brain tumor headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain tumor headache frequently mimics TTH. Intracranial tumors are associated with headache at initial presentation in approximately 20 percent, while headache is present in approximately 60 percent during the course of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/55\">",
"     55",
"    </a>",
"    ]. A retrospective review of 111 patients with brain tumors found that headaches were present in 48 percent of cases with either primary or metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/56\">",
"     56",
"    </a>",
"    ]. The headaches were similar to TTH, migraine, or other types in 77, 9, and 14 percent, respectively. Unlike primary TTH, such headaches may be worse unilaterally, worse when bending over, or associated with nausea or vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=see_link\">",
"     \"Clinical presentation and diagnosis of brain tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because pure TTH is uncommon in the office, practitioners must be especially vigilant about the possibility of brain tumor when patients present with a new, subacute, or progressive headache suggestive of TTH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Medication overuse headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medication overuse headache (MOH) is a commonly encountered type of secondary headache that should be suspected in patients who have frequent or daily headaches despite, or because of, the regular use of headache medications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=see_link&amp;anchor=H8#H8\">",
"     \"Headache syndromes other than migraine\", section on 'Medication overuse headache'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MOH diagnostic criteria are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/57\">",
"     57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Headache present on &ge;15",
"      <span class=\"nowrap\">",
"       days/month",
"      </span>",
"     </li>",
"     <li>",
"      Regular overuse for &gt;3 months of one or more",
"      <span class=\"nowrap\">",
"       acute/symptomatic",
"      </span>",
"      treatment drugs:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/20/23877?source=see_link\">",
"       Ergotamine",
"      </a>",
"      , triptans, opioids, or combination analgesic medications on &ge;10",
"      <span class=\"nowrap\">",
"       days/month",
"      </span>",
"      on a regular basis for &gt;3 months",
"     </li>",
"     <li>",
"      Simple analgesics or any combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      , triptans, analgesics, or opioids on &ge;15",
"      <span class=\"nowrap\">",
"       days/month",
"      </span>",
"      on a regular basis for &gt;3 months without overuse of any single class alone",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Headache has developed or markedly worsened during medication overuse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goal of therapy for MOH headaches is cessation of the offending medications through drug withdrawal and detoxification.",
"   </p>",
"   <p>",
"    MOH represents a significant problem in patients with primary TTH, as such patients suffer stronger withdrawal symptoms on clean-out and have significantly higher relapse rates than patients with other MOH and primary headache types at both one and four-year prospective follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. This is probably due, at least in part, to the withdrawal patterns peculiar to different agents used for different types of headache, since overuse of mixed analgesics was associated with a significantly higher relapse rate than overuse of triptans (typically used for migraine) at one year after drug withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Sinus headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus headache is commonly diagnosed by clinicians and self-diagnosed by patients, but acute or chronic sinusitis appears to be an uncommon cause of recurrent headaches, and many patients presenting with sinus headache turn out to have migraine or, less often, TTH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=see_link&amp;anchor=H17#H17\">",
"     \"Headache syndromes other than migraine\", section on 'Sinus headache'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The occurrence of nasal symptoms associated with headache in the region of the sinuses, without fever or purulent nasal discharge, should neither trigger a diagnosis of sinus headache nor exclude the diagnosis of other primary headaches, including TTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Cervicogenic headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervicogenic headache should be considered if headache is strictly unilateral [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/43/32441/abstract/62\">",
"     62",
"    </a>",
"    ]. Cervicogenic headache is a controversial entity caused by referred pain from the upper cervical joints. This type of headache is characterized by unilateral nonthrobbing, nonlancinating head pain of moderate to severe intensity and variable duration that is increased by movement of the head and radiates from occipital to frontal regions. The proposed clinical features of cervicogenic headache may mimic those commonly associated with primary headache disorders, including TTH. Muscle tenderness in the posterior head and upper neck is a primary diagnostic criterion of cervicogenic headache, and is common in TTH as well.",
"   </p>",
"   <p>",
"    While there is no consensus, a practical approach for establishing the diagnosis of cervicogenic headache relies on the use of controlled anesthetic blocks of cervical structures or their nerve supply. These anesthetic blocks are believed (by many but not all experts) to pinpoint sources of pain in the neck when they provide complete, momentary relief of pain.",
"   </p>",
"   <p>",
"    Cervicogenic headache is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/60/26568?source=see_link\">",
"     \"Cervicogenic headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Other secondary headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarer entities such as spontaneous low volume cerebrospinal fluid syndromes, chronic meningitis, and others may occasionally be associated with headaches that resemble TTH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/20/330?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/20/4424?source=see_link\">",
"     \"Approach to the patient with chronic meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=see_link\">",
"       \"Patient information: Headache (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/51/16179?source=see_link\">",
"       \"Patient information: Headache causes and diagnosis in adults (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The typical presentation of a tension-type headache (TTH) attack is that of a mild to moderate intensity, bilateral, nonthrobbing headache without other associated features. Pure TTH is a rather featureless headache. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Heightened sensitivity of pain pathways in the central nervous system, and perhaps in the peripheral nervous system, is thought to play a critical role in the pathogenesis of TTH. Nitric oxide may be a molecular trigger for pain. Genetic factors seem to play a minor role in episodic TTH but may be more important in chronic TTH. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three main subtypes of TTH (",
"      <a class=\"graphic graphic_table graphicRef79672 \" href=\"mobipreview.htm?42/32/43531\">",
"       table 1",
"      </a>",
"      ). Each of the subtypes is additionally classified as occurring with or without pericranial muscle tenderness. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infrequent episodic TTH, with headaches &lt;1 day a month",
"     </li>",
"     <li>",
"      Frequent episodic TTH, with headaches 1 to 14 days a month",
"     </li>",
"     <li>",
"      Chronic TTH, with headaches &ge;15 days a month",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TTH is the most prevalent type of primary headache in the general population, but most patients with TTH have the infrequent episodic subtype, with headaches less than one day a month. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pericranial muscle tenderness is associated with both the intensity and the frequency of TTH attacks. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of TTH is made when the patient's description of the attacks is consistent with the typical features of TTH, the diagnostic criteria are fulfilled (",
"      <a class=\"graphic graphic_table graphicRef79672 \" href=\"mobipreview.htm?42/32/43531\">",
"       table 1",
"      </a>",
"      ), and the general and neurologic examinations are normal, with the exception of the presence or absence of pericranial muscle tenderness and temporal patterns do not raise concern for secondary headache. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuroimaging is not necessary in most patients with primary headaches, including those with TTH, who have a stable headache pattern for over six months and a normal neurologic examination. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnostic testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=see_link&amp;anchor=H7#H7\">",
"       \"Evaluation of headache in adults\", section on 'Danger signs on history'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=see_link&amp;anchor=H11#H11\">",
"       \"Evaluation of headache in adults\", section on 'Indications for imaging studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Because of the association of TTH-like symptoms with secondary headaches, including those due to medication overuse or structural brain lesions, we suggest that practitioners consider the possibility of a secondary headache disorder when patients present with presumed TTH. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Secondary headaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic challenges occur in the evaluation of suspected TTH when there are atypical or absent features, when features overlap with other types of headaches, and when patients fail to report all symptoms. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnostic challenges'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/1\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/2\">",
"      Bendtsen L. Central sensitization in tension-type headache--possible pathophysiological mechanisms. Cephalalgia 2000; 20:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/3\">",
"      Jensen R. Peripheral and central mechanisms in tension-type headache: an update. Cephalalgia 2003; 23 Suppl 1:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/4\">",
"      Ulrich V, Gervil M, Olesen J. The relative influence of environment and genes in episodic tension-type headache. Neurology 2004; 62:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/5\">",
"      Russell MB, Ostergaard S, Bendtsen L, Olesen J. Familial occurrence of chronic tension-type headache. Cephalalgia 1999; 19:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/6\">",
"      Russell MB, Iselius L, Ostergaard S, Olesen J. Inheritance of chronic tension-type headache investigated by complex segregation analysis. Hum Genet 1998; 102:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/7\">",
"      Bendtsen L. Central and peripheral sensitization in tension-type headache. Curr Pain Headache Rep 2003; 7:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/8\">",
"      Bezov D, Ashina S, Jensen R, Bendtsen L. Pain perception studies in tension-type headache. Headache 2011; 51:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/9\">",
"      Bendtsen L, Fumal A, Schoenen J. Tension-type headache: mechanisms. Handb Clin Neurol 2010; 97:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/10\">",
"      Schmidt-Wilcke T, Leinisch E, Straube A, et al. Gray matter decrease in patients with chronic tension type headache. Neurology 2005; 65:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/11\">",
"      Bendtsen L, Fern&aacute;ndez-de-la-Pe&ntilde;as C. The role of muscles in tension-type headache. Curr Pain Headache Rep 2011; 15:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/12\">",
"      Zagami AS. Pathophysiology of migraine and tension-type headache. Curr Opin Neurol 1994; 7:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/13\">",
"      Ashina M. Neurobiology of chronic tension-type headache. Cephalalgia 2004; 24:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/14\">",
"      Langemark M, Jensen K, Jensen TS, Olesen J. Pressure pain thresholds and thermal nociceptive thresholds in chronic tension-type headache. Pain 1989; 38:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/15\">",
"      Schoenen J, Bottin D, Hardy F, Gerard P. Cephalic and extracephalic pressure pain thresholds in chronic tension-type headache. Pain 1991; 47:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/16\">",
"      Bendtsen L, Jensen R, Olesen J. Decreased pain detection and tolerance thresholds in chronic tension-type headache. Arch Neurol 1996; 53:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/17\">",
"      Schoenen J. Depression in tension-type headache sufferers: bystander or villain? Pain 2004; 111:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/18\">",
"      de Tommaso M, Ceci E, Pica C, et al. Serum levels of N-acetyl-aspartate in migraine and tension-type headache. J Headache Pain 2012; 13:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/19\">",
"      Fischer M, Wille G, Klien S, et al. Brain-derived neurotrophic factor in primary headaches. J Headache Pain 2012; 13:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/20\">",
"      Fern&aacute;ndez-de-Las-Pe&ntilde;as C, Cuadrado ML, Pareja JA. Myofascial trigger points, neck mobility, and forward head posture in episodic tension-type headache. Headache 2007; 47:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/21\">",
"      Fern&aacute;ndez-de-Las-Pe&ntilde;as C, Alonso-Blanco C, Cuadrado ML, et al. Myofascial trigger points and their relationship to headache clinical parameters in chronic tension-type headache. Headache 2006; 46:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/22\">",
"      Fern&aacute;ndez-de-las-Pe&ntilde;as C, Alonso-Blanco C, Cuadrado ML, et al. Trigger points in the suboccipital muscles and forward head posture in tension-type headache. Headache 2006; 46:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/23\">",
"      Ashina S, Bendtsen L, Ashina M. Pathophysiology of tension-type headache. Curr Pain Headache Rep 2005; 9:415.",
"     </a>",
"    </li>",
"    <li>",
"     Scher, AI, Stewart, WF, Lipton, RB. Migraine and headache: a meta-analytic approach. In Epidemiology of Pain, Crombie, IK (Ed), IASP Press, Seattle 1999. p.159.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/25\">",
"      Russell MB, Levi N, Saltyte-Benth J, Fenger K. Tension-type headache in adolescents and adults: a population based study of 33,764 twins. Eur J Epidemiol 2006; 21:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/26\">",
"      Lyngberg AC, Rasmussen BK, J&oslash;rgensen T, Jensen R. Has the prevalence of migraine and tension-type headache changed over a 12-year period? A Danish population survey. Eur J Epidemiol 2005; 20:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/27\">",
"      Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. JAMA 1998; 279:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/28\">",
"      Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population--a prevalence study. J Clin Epidemiol 1991; 44:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/29\">",
"      Russell MB. Tension-type headache in 40-year-olds: a Danish population-based sample of 4000. J Headache Pain 2005; 6:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/30\">",
"      Wang SJ, Liu HC, Fuh JL, et al. Prevalence of headaches in a Chinese elderly population in Kinmen: age and gender effect and cross-cultural comparisons. Neurology 1997; 49:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/31\">",
"      Couch JR. The long-term prognosis of tension-type headache. Curr Pain Headache Rep 2005; 9:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/32\">",
"      Stovner Lj, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007; 27:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/33\">",
"      Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol 2008; 7:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/34\">",
"      Bendtsen L, Jensen R. Tension-type headache: the most common, but also the most neglected, headache disorder. Curr Opin Neurol 2006; 19:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/35\">",
"      Rasmussen BK. Epidemiology of headache. Cephalalgia 1995; 15:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/36\">",
"      Jensen R, Rasmussen BK, Pedersen B, Olesen J. Muscle tenderness and pressure pain thresholds in headache. A population study. Pain 1993; 52:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/37\">",
"      Sandrini G, Antonaci F, Pucci E, et al. Comparative study with EMG, pressure algometry and manual palpation in tension-type headache and migraine. Cephalalgia 1994; 14:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/38\">",
"      Jensen R, Fuglsang-Frederiksen A. Quantitative surface EMG of pericranial muscles. Relation to age and sex in a general population. Electroencephalogr Clin Neurophysiol 1994; 93:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/39\">",
"      Ashina M, Stallknecht B, Bendtsen L, et al. Tender points are not sites of ongoing inflammation -in vivo evidence in patients with chronic tension-type headache. Cephalalgia 2003; 23:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/40\">",
"      Spierings EL, Ranke AH, Honkoop PC. Precipitating and aggravating factors of migraine versus tension-type headache. Headache 2001; 41:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/41\">",
"      Rasmussen BK. Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle. Pain 1993; 53:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/42\">",
"      Ulrich V, Russell MB, Jensen R, Olesen J. A comparison of tension-type headache in migraineurs and in non-migraineurs: a population-based study. Pain 1996; 67:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/43\">",
"      Karli N, Zarifoglu M, Calisir N, Akgoz S. Comparison of pre-headache phases and trigger factors of migraine and episodic tension-type headache: do they share similar clinical pathophysiology? Cephalalgia 2005; 25:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/44\">",
"      Buchgreitz L, Lyngberg AC, Bendtsen L, Jensen R. Increased prevalence of tension-type headache over a 12-year period is related to increased pain sensitivity. A population study. Cephalalgia 2007; 27:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/45\">",
"      Buchgreitz L, Lyngberg AC, Bendtsen L, Jensen R. Frequency of headache is related to sensitization: a population study. Pain 2006; 123:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/46\">",
"      Rasmussen BK, Jensen R, Schroll M, Olesen J. Interrelations between migraine and tension-type headache in the general population. Arch Neurol 1992; 49:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/47\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/48\">",
"      Dowson AJ. Assessing the impact of migraine. Curr Med Res Opin 2001; 17:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/49\">",
"      Tepper SJ, Dahl&ouml;f CG, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache 2004; 44:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/50\">",
"      Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988; 8 Suppl 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/51\">",
"      Lipton RB, Cady RK, Stewart WF, et al. Diagnostic lessons from the spectrum study. Neurology 2002; 58:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/52\">",
"      Lipton RB, Stewart WF, Cady R, et al. 2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 2000; 40:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/53\">",
"      Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996; 47:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/54\">",
"      Silberstein SD. Chronic daily headache. J Am Osteopath Assoc 2005; 105:23S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/55\">",
"      Jaeckle KA. Causes and management of headaches in cancer patients. Oncology (Williston Park) 1993; 7:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/56\">",
"      Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology 1993; 43:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/57\">",
"      Headache Classification Committee, Olesen J, Bousser MG, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/58\">",
"      Katsarava Z, Limmroth V, Finke M, et al. Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology 2003; 60:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/59\">",
"      Katsarava Z, Muessig M, Dzagnidze A, et al. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 2005; 25:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/60\">",
"      Bigal ME, Lipton RB. Tension-type headache: classification and diagnosis. Curr Pain Headache Rep 2005; 9:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/61\">",
"      Cady RK, Schreiber CP. Sinus headache or migraine? Considerations in making a differential diagnosis. Neurology 2002; 58:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/43/32441/abstract/62\">",
"      Bendtsen L, Evers S, Linde M, et al. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol 2010; 17:1318.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3357 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-F656983DA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32441=[""].join("\n");
var outline_f31_43_32441=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Heightened sensitivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Central factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Peripheral factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Societal impact",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pericranial muscle tenderness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Precipitating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Relationship with migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSTIC CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Episodic tension-type headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chronic tension-type headache",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Secondary headaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Brain tumor headache",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Medication overuse headache",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Sinus headache",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Cervicogenic headache",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Other secondary headaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/3357\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/3357|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/32/43531\" title=\"table 1\">",
"      Tension-type headache criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/23/20859\" title=\"table 2\">",
"      Long duration chronic daily headache",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/20/4424?source=related_link\">",
"      Approach to the patient with chronic meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/60/26568?source=related_link\">",
"      Cervicogenic headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/3/25657?source=related_link\">",
"      Clinical presentation and diagnosis of brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7594?source=related_link\">",
"      Etiology, clinical features, and diagnosis of cerebral venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=related_link\">",
"      Evaluation of headache in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=related_link\">",
"      Headache syndromes other than migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/20/330?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of spontaneous low cerebrospinal fluid pressure headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/31/3570?source=related_link\">",
"      Patient information: Headache (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/51/16179?source=related_link\">",
"      Patient information: Headache causes and diagnosis in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/13/37079?source=related_link\">",
"      Tension-type headache in adults: Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/25/1433?source=related_link\">",
"      Tension-type headache in adults: Preventive treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/59/34744?source=related_link\">",
"      Tension-type headache in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12601?source=related_link\">",
"      Thunderclap headache",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_43_32442="Ethinyl estradiol and norethindrone: Drug information";
var content_f31_43_32442=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol and norethindrone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/19/311?source=see_link\">",
"    see \"Ethinyl estradiol and norethindrone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alyacen 1/35;",
"     </li>",
"     <li>",
"      Alyacen 7/7/7;",
"     </li>",
"     <li>",
"      Aranelle&reg;;",
"     </li>",
"     <li>",
"      Balziva&trade;;",
"     </li>",
"     <li>",
"      Brevicon&reg;;",
"     </li>",
"     <li>",
"      Briellyn;",
"     </li>",
"     <li>",
"      Cyclafem&trade; 1/35;",
"     </li>",
"     <li>",
"      Cyclafem&trade; 7/7/7;",
"     </li>",
"     <li>",
"      Dasetta&trade; 1/35;",
"     </li>",
"     <li>",
"      Dasetta&trade; 7/7/7;",
"     </li>",
"     <li>",
"      Estrostep&reg; Fe;",
"     </li>",
"     <li>",
"      Femcon&reg; Fe;",
"     </li>",
"     <li>",
"      femhrt&reg;;",
"     </li>",
"     <li>",
"      femhrt&reg; Lo;",
"     </li>",
"     <li>",
"      Generess&trade; Fe;",
"     </li>",
"     <li>",
"      Gildess&reg; FE 1.5/30;",
"     </li>",
"     <li>",
"      Gildess&reg; FE 1/20;",
"     </li>",
"     <li>",
"      Jevantique&trade; [DSC];",
"     </li>",
"     <li>",
"      Jinteli&trade;;",
"     </li>",
"     <li>",
"      Junel&reg; 1.5/30;",
"     </li>",
"     <li>",
"      Junel&reg; 1/20;",
"     </li>",
"     <li>",
"      Junel&reg; Fe 1.5/30;",
"     </li>",
"     <li>",
"      Junel&reg; Fe 1/20;",
"     </li>",
"     <li>",
"      Leena&reg;;",
"     </li>",
"     <li>",
"      Lo Loestrin&trade; Fe;",
"     </li>",
"     <li>",
"      Loestrin&reg; 21 1.5/30;",
"     </li>",
"     <li>",
"      Loestrin&reg; 21 1/20;",
"     </li>",
"     <li>",
"      Loestrin&reg; 24 Fe;",
"     </li>",
"     <li>",
"      Loestrin&reg; Fe 1.5/30;",
"     </li>",
"     <li>",
"      Loestrin&reg; Fe 1/20;",
"     </li>",
"     <li>",
"      Microgestin&reg; 1.5/30;",
"     </li>",
"     <li>",
"      Microgestin&reg; 1/20;",
"     </li>",
"     <li>",
"      Microgestin&reg; Fe 1.5/30;",
"     </li>",
"     <li>",
"      Microgestin&reg; Fe 1/20;",
"     </li>",
"     <li>",
"      Modicon&reg;;",
"     </li>",
"     <li>",
"      Necon&reg; 0.5/35;",
"     </li>",
"     <li>",
"      Necon&reg; 1/35;",
"     </li>",
"     <li>",
"      Necon&reg; 10/11;",
"     </li>",
"     <li>",
"      Necon&reg; 7/7/7;",
"     </li>",
"     <li>",
"      Norinyl&reg; 1+35;",
"     </li>",
"     <li>",
"      Nortrel&reg; 0.5/35;",
"     </li>",
"     <li>",
"      Nortrel&reg; 1/35;",
"     </li>",
"     <li>",
"      Nortrel&reg; 7/7/7;",
"     </li>",
"     <li>",
"      Ortho-Novum&reg; 1/35;",
"     </li>",
"     <li>",
"      Ortho-Novum&reg; 7/7/7;",
"     </li>",
"     <li>",
"      Ovcon&reg; 35;",
"     </li>",
"     <li>",
"      Ovcon&reg; 50 [DSC];",
"     </li>",
"     <li>",
"      Tilia&trade; Fe;",
"     </li>",
"     <li>",
"      Tri-Legest&trade; Fe;",
"     </li>",
"     <li>",
"      Tri-Norinyl&reg;;",
"     </li>",
"     <li>",
"      Wera&trade;;",
"     </li>",
"     <li>",
"      Wymzya&trade; Fe;",
"     </li>",
"     <li>",
"      Zenchent Fe&trade;;",
"     </li>",
"     <li>",
"      Zenchent&reg;;",
"     </li>",
"     <li>",
"      Zeosa&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Brevicon&reg; 0.5/35;",
"     </li>",
"     <li>",
"      Brevicon&reg; 1/35;",
"     </li>",
"     <li>",
"      FemHRT&reg;;",
"     </li>",
"     <li>",
"      Loestrin&trade; 1.5/30;",
"     </li>",
"     <li>",
"      Minestrin&trade; 1/20;",
"     </li>",
"     <li>",
"      Ortho&reg; 0.5/35;",
"     </li>",
"     <li>",
"      Ortho&reg; 1/35;",
"     </li>",
"     <li>",
"      Ortho&reg; 7/7/7;",
"     </li>",
"     <li>",
"      Select&trade; 1/35;",
"     </li>",
"     <li>",
"      Synphasic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F168488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Contraceptive;",
"     </li>",
"     <li>",
"      Estrogen and Progestin Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F168472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;15 years and Adults: Females: Acne: Estrostep&reg; Fe: Oral: Refer to dosing for contraception",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate-to-severe vasomotor symptoms associated with menopause: Initial: femhrt&reg; 0.5/2.5: Oral: 1 tablet daily; patient should be re-evaluated at 3- to 6-month intervals to determine if treatment is still necessary; patient should be maintained on lowest effective dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of osteoporosis: Initial: femhrt&reg; 0.5/2.5: Oral: 1 tablet daily; patient should be maintained on lowest effective dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Contraception: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Dose begins on first Sunday after onset of menstruation; if the menstrual period starts on Sunday, take first tablet that very same day. This schedule is not preferred for Lo Loestrin&trade; Fe. With a Sunday start, an additional method of contraception should be used until after the first 7 days of consecutive administration (all products).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 21-tablet package: Dosage is 1 tablet daily for 21 consecutive days, followed by 7 days off of the medication; a new course begins on the 8th day after the last tablet is taken.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 28-tablet package: Dosage is 1 tablet daily without interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Schedule 2 (Day 1 starter): Dose starts on first day of menstrual cycle taking 1 tablet daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 21-tablet package: Dosage is 1 tablet daily for 21 consecutive days, followed by 7 days off of the medication; a new course begins on the 8th day after the last tablet is taken.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For 28-tablet package: Dosage is 1 tablet daily without interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If all doses have been taken on schedule and one menstrual period is missed, continue dosing cycle. If two consecutive menstrual periods are missed, pregnancy test is required before new dosing cycle is started.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Missed doses",
"     <b>",
"      monophasic formulations",
"     </b>",
"     (refer to package insert for complete information):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     One dose missed: Take as soon as remembered. Take the next tablet at your regular time. You may take 2 tablets in 1 day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Two consecutive doses missed in the first 2 weeks: Take 2 tablets as soon as remembered and 2 tablets the next day. An additional method of contraception should be used for 7 days after missed dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Two consecutive doses missed in week 3 (all products) or in week 4 (Lo Loestrin&trade; Fe), or three consecutive doses missed at any time (all products): An additional method of contraception must be used for 7 days after a missed dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 1 (Sunday starter): Continue dose of 1 tablet daily until Sunday, then discard the rest of the pack, and a new pack should be started that same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 2 (Day 1 starter): Current pack should be discarded, and a new pack should be started that same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Missed doses",
"     <b>",
"      biphasic/triphasic formulations",
"     </b>",
"     (refer to package insert for complete information):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     One dose missed: Take as soon as remembered. Take the next tablet at your regular time. You may take 2 tablets in 1 day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Two consecutive doses missed in week 1 or week 2 of the pack: Take 2 tablets as soon as remembered and 2 tablets the next day. Resume taking 1 tablet daily until the pack is empty. An additional method of contraception should be used for 7 days after a missed dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Two consecutive doses missed in week 3 of the pack: An additional method of contraception must be used for 7 days after a missed dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 1 (Sunday Starter): Take 1 tablet every day until Sunday. Discard the remaining pack and start a new pack of pills on the same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 2 (Day 1 starter): Discard the remaining pack and start a new pack the same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Three or more consecutive doses missed: An additional method of contraception must be used for 7 days after a missed dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 1 (Sunday Starter): Take 1 tablet every day until Sunday; on Sunday, discard the pack and start a new pack.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Schedule 2 (Day 1 Starter): Discard the remaining pack and begin new pack of tablets starting on the same day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Switching from a different contraceptive:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Oral contraceptive: Start on the same day that a new pack of the previous oral contraceptive would have been taken.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Transdermal patch, vaginal ring, injection: Start on the day the next dose would have been due.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     IUD or implant: Start on the day of removal. A backup method of contraception may be required following IUD removal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Use after childbirth (in women who are not breast-feeding) or after second trimester abortion:",
"     </b>",
"     Therapy may be started &ge;4 weeks postpartum. Pregnancy should be ruled out prior to treatment if menstrual periods have not restarted and an additional method of contraception (nonhormonal) should be used until after the first 7 days of consecutive administration.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F168482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne:",
"     </b>",
"     Oral (Estrostep&reg; Fe): For use in females &ge;15 years; refer to adult dosing for contraception",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Contraception:",
"     </b>",
"     Oral: Refer to adult dosing; not to be used prior to menarche.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3182139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F168473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific guidelines not available; use with caution and monitor blood pressure closely. Consider other forms of contraception.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F168474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in patients with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F168442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     femhrt&reg; 1/5: Ethinyl estradiol 0.005 mg and norethindrone acetate 1 mg [white tablets] (28s, 90s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     femhrt&reg; Lo 0.5/2.5: Ethinyl estradiol 0.0025 mg and norethindrone acetate 0.5 mg [white tablets] (28s, 90s[DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Jevantique&trade; 1/5:  Ethinyl estradiol 0.005 mg and norethindrone acetate 1 mg [white tablets] (28s, 90s) [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Jinteli&trade;: Ethinyl estradiol 0.005 mg and norethindrone acetate 1 mg [white tablets] (28s, 90s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral [monophasic formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alyacen 1/35: Ethinyl estradiol 0.035 mg and norethindrone 1 mg [21 peach tablets and 7 light green inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Balziva&trade;: Ethinyl estradiol 0.035 mg and norethindrone 0.4 mg [21 light peach tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brevicon&reg;: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [21 blue tablets and 7 orange inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Briellyn: Ethinyl estradiol 0.035 mg and norethindrone 0.4 mg [21 light peach tablets and 7 white-off-white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyclafem&trade; 1/35: Ethinyl estradiol 0.035 mg and norethindrone 1 mg [21 pink tablets and 7 light green inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dasetta&trade; 1/35: Ethinyl estradiol 0.035 mg and norethindrone 1 mg [21 orange tablets and 7 white inactive tablets] (28s) [contains soya lecithin, tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gildess&reg; FE 1/20: Ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg [21 white tablets] and ferrous fumarate 75 mg [7 white-speckled brown tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gildess&reg; FE 1.5/30: Ethinyl estradiol 0.03 mg and norethindrone acetate 1.5 mg [21 light green tablets] and ferrous fumarate 75 mg [7 white-speckled brown tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Junel&reg; 1/20: Ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg [yellow tablets] (21s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Junel&reg; 1.5/30: Ethinyl estradiol 0.03 mg and norethindrone acetate 1.5 mg [pink tablets] (21s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Junel&reg; Fe 1/20: Ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg [21 yellow tablets] and ferrous fumarate 75 mg [7 brown tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Junel&reg; Fe 1.5/30: Ethinyl estradiol 0.03 mg and norethindrone acetate 1.5 mg [21 pink tablets] and ferrous fumarate 75 mg [7 brown tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loestrin&reg; 21 1/20: Ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg [light yellow tablets] (21s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loestrin&reg; 21 1.5/30: Ethinyl estradiol 0.03 mg and norethindrone acetate 1.5 mg [pink tablets] (21s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lo Loestrin&trade; Fe: Ethinyl estradiol 0.01 mg and norethindrone acetate 1mg [24 blue tablets] and ethinyl estradiol 0.01 mg [2 white tablets] and ferrous fumarate 75 mg [2 brown tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loestrin&reg; 24 Fe: Ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg [24 white tablets] and ferrous fumarate 75 mg [4 brown tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loestrin&reg; Fe 1/20: Ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg [21 light yellow tablets] and ferrous fumarate 75 mg [7 brown tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loestrin&reg; Fe 1.5/30: Ethinyl estradiol 0.03 mg and norethindrone acetate 1.5 mg [21 pink tablets] and ferrous fumarate 75 mg [7 brown tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Microgestin&reg; 1/20: Ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg [white tablets] (21s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Microgestin&reg; 1.5/30: Ethinyl estradiol 0.03 mg and norethindrone acetate 1.5 mg [green tablets] (21s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Microgestin&reg; Fe 1/20: Ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg [21 white tablets] and ferrous fumarate 75 mg [7 brown tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Microgestin&reg; Fe 1.5/30: Ethinyl estradiol 0.03 mg and norethindrone acetate 1.5 mg [21 green tablets] and ferrous fumarate 75 mg [7 brown tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Modicon&reg;: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [21 white tablets and 7 green inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Necon&reg; 0.5/35: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [21 light yellow tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Necon&reg; 1/35: Ethinyl estradiol 0.035 mg and norethindrone 1 mg [21 dark yellow tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norinyl&reg; 1+35: Ethinyl estradiol 0.035 mg and norethindrone 1 mg [21 yellow-green tablets and 7 orange inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nortrel&reg; 0.5/35: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [21 light yellow tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nortrel&reg; 1/35:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ethinyl estradiol 0.035 mg and norethindrone 1 mg [yellow tablets] (21s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ethinyl estradiol 0.035 mg and norethindrone 1 mg [21 yellow tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ortho-Novum&reg; 1/35: Ethinyl estradiol 0.035 mg and norethindrone 1 mg [21 peach tablets and 7 green inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ovcon&reg; 35: Ethinyl estradiol 0.035 mg and norethindrone 0.4 mg [21 light peach tablets and 7 green inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ovcon&reg; 50: Ethinyl estradiol 0.05 mg and norethindrone 1 mg [21 yellow tablets and 7 green inactive tablets] (28s) [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wera&trade;: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [21 light peach tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zenchent&reg;: Ethinyl estradiol 0.035 mg and norethindrone 0.4 mg [21 orange tablets and 7 white inactive tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Tablet, chewable, oral [monophasic formulation]: Ethinyl estradiol 0.035 mg and norethindrone 0.4 mg [21 tablets] and ferrous fumarate 75 mg [7 tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Femcon&reg; Fe: Ethinyl estradiol 0.035 mg and norethindrone 0.4 mg [21 white tablets] and ferrous fumarate 75 mg [7 brown tablets] [spearmint flavor] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Generess&trade; Fe: Ethinyl estradiol 0.025 mg and norethindrone 0.8 mg [24 light green tablets] and ferrous fumarate 75 mg [4 brown tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Wymzya&trade; Fe: Ethinyl estradiol 0.035 mg and norethindrone 0.4 mg [21 white tablets] and ferrous fumarate 75 mg [7 brown tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Zenchent Fe&trade;: Ethinyl estradiol 0.035 mg and  norethindrone 0.4 mg [21 light yellow tablets] and ferrous fumarate 75 mg [7 brown tablets] [spearmint flavor] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Zeosa&trade;: Ethinyl estradiol 0.035 mg and norethindrone 0.4 mg [21 light yellow tablets] and ferrous fumarate 75 mg [7 brown tablets] [spearmint flavor] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral [biphasic formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Necon&reg; 10/11:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-10: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [10 light yellow tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 11-21: Ethinyl estradiol 0.035 mg and norethindrone 1 mg [11 dark yellow tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 white inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Tablet, oral [triphasic formulation]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alyacen 7/7/7:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [7 white-off-white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-14: Ethinyl estradiol 0.035 mg and norethindrone 0.75 mg [7 light peach tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 15-21: Ethinyl estradiol 0.035 mg and norethindrone 1 mg [7 peach tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 light green inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aranelle&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [7 light yellow tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-16: Ethinyl estradiol 0.035 mg and norethindrone 1 mg [9 white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 17-21: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [5 light yellow tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 peach inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cyclafem&trade; 7/7/7:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [7 white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-14: Ethinyl estradiol 0.035 mg and norethindrone 0.75 mg [7 light pink tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 15-21: Ethinyl estradiol 0.035 mg and norethindrone 1 mg [7 pink tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 light green inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dasetta&trade; 7/7/7:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [7 light peach tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-14: Ethinyl estradiol 0.035 mg and norethindrone 0.75 mg [7 peach tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 15-21: Ethinyl estradiol 0.035 mg and norethindrone 1 mg [7 orange tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 white inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Estrostep&reg; Fe:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-5: Ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg [5 white triangular tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 6-12: Ethinyl estradiol 0.03 mg and norethindrone acetate 1 mg [7 white square tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 13-21: Ethinyl estradiol 0.035 mg and norethindrone acetate 1 mg [9 white round tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: Ferrous fumarate 75 mg [7 brown tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Leena&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [7 light blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-16: Ethinyl estradiol 0.035 mg and norethindrone 1 mg [9 light yellow-green tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 17-21: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [5 light blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 orange inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Necon&reg; 7/7/7, Ortho-Novum&reg; 7/7/7:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [7 white tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-14: Ethinyl estradiol 0.035 mg and norethindrone 0.75 mg [7 light peach tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 15-21: Ethinyl estradiol 0.035 mg and norethindrone 1 mg [7 peach tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 green inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nortrel&reg; 7/7/7:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [7 light yellow tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-14: Ethinyl estradiol 0.035 mg and norethindrone 0.75 mg [7 blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 15-21: Ethinyl estradiol 0.035 mg and norethindrone 1 mg [7 peach tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 white inactive tablets (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tilia&trade; Fe:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-5: Ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg [5 white triangular tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 6-12: Ethinyl estradiol 0.03 mg and norethindrone acetate 1 mg [7 white square tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 13-21: Ethinyl estradiol 0.035 mg and norethindrone acetate 1 mg [9 white round tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: Ferrous fumarate 75 mg [7 brown tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tri-Legest&trade; Fe:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-5: Ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg [5 light pink tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 6-12: Ethinyl estradiol 0.03 mg and norethindrone acetate 1 mg [7 light yellow tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 13-21: Ethinyl estradiol 0.035 mg and norethindrone acetate 1 mg [9 light blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: Ferrous fumarate 75 mg [7 brown tablets] (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tri-Norinyl&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 1-7: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [7 blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 8-16: Ethinyl estradiol 0.035 mg and norethindrone 1 mg [9 yellow-green tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 17-21: Ethinyl estradiol 0.035 mg and norethindrone 0.5 mg [5 blue tablets]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Day 22-28: 7 orange inactive tablets (28s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F168425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F168444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time each day; without regard to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lo Loestrin&trade; Fe: If vomiting or diarrhea occurs within 3-4 hours of a dose, consider the dose to be missed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F168443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of pregnancy; treatment of acne; moderate-to-severe vasomotor symptoms associated with menopause; prevention of osteoporosis (in women at significant risk only)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F168485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypermenorrhea (menorrhagia); pain associated with endometriosis, dysmenorrhea; dysfunctional uterine bleeding",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F168496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       femhrt&reg; may be confused with Femara&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lo Loestrin&trade; Fe may be confused with Loestrin&reg; Fe",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Modicon&reg; may be confused with Mylicon&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Norinyl&reg; may be confused with Nardil&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F168486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The following reactions have been associated with oral contraceptive use:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Increased risk or evidence of association with use:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arterial thromboembolism, cerebral hemorrhage, cerebral thrombosis, hypertension, mesenteric thrombosis, MI, venous thrombosis (with or without embolism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gallbladder disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hepatic adenomas, liver tumors (benign)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Retinal thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Impaired renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Adverse reactions considered drug related:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema, varicose vein aggravation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression, migraine, mood changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Chloasma, melasma, rash (allergic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breakthrough bleeding, breast changes (enlargement, pain, secretion, tenderness), fluid retention, infertility (temporary), lactation decreased (with use immediately postpartum), menstrual flow changes, spotting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal bloating, abdominal cramps, abdominal pain, appetite changes, nausea, weight changes, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Cervical ectropion, cervical secretion, vaginal candidiasis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Folate decreased, porphyria exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chorea exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Contact lens intolerance, corneal curvature changes (steepening)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic/anaphylactoid reactions (including angioedema, circulatory collapse, respiratory collapse, urticaria), SLE exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Adverse reactions in which association is not confirmed or denied:",
"     </i>",
"     Acne, Budd-Chiari syndrome, cataracts, colitis, cystitis-like syndrome, dizziness, dysmenorrhea, erythema multiforme, erythema nodosum, headache, hemolytic uremic syndrome, hemorrhagic eruption, hirsutism, libido changes, nervousness, optic neuritis (with or without partial or complete loss of vision), pancreatitis, premenstrual syndrome, renal function impaired, scalp hair loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      The following have been associated with femhrt&reg;",
"     </b>",
"     and in general, are similar to placebo. Also refer to adverse reactions observed with oral contraceptives for additional reactions observed with estrogen/progestin therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (15% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Depression (4% to 6%), nervousness (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain (8% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (8% to 10%), nausea/vomiting (5% to 7%), diarrhea (4% to 6%), dyspepsia (3% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (4% to 6%), vaginitis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Sinusitis (8% to 9%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F168447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Angioedema, anaphylactic reaction, or hypersensitivity to ethinyl estradiol, norethindrone, norethindrone acetate, or any component of the formulation; breast cancer or other estrogen- or progestin-dependent neoplasms (current or a history of), hepatic tumors or disease, pregnancy, undiagnosed abnormal uterine bleeding",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use is also contraindicated in women at high risk of arterial or venous thrombotic diseases including: Cerebrovascular disease, coronary artery disease, diabetes mellitus with vascular disease, DVT or PE (current or history of), hypercoagulopathies (inherited or acquired), headaches with focal neurological symptoms, hypertension (uncontrolled), migraine headaches if &gt;35 years of age, thrombogenic valvular or rhythm diseases of the heart (eg, subacute bacterial endocarditis with valvular disease or atrial fibrillation), women &gt;35 years of age who smoke.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F168429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).",
"     </b>",
"     This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012). An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Estrogen use may lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs. The use of combination hormonal contraceptives has been associated with a slight increase in frequency of breast cancer; however, studies are not consistent. Use is contraindicated in patients with known or suspected breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chloasma: Use caution with a history of chloasma gravidarum; women with a tendency to chloasma should avoid sun and ultraviolet radiation exposure during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometrial carcinoma:",
"     <b>",
"      [U.S. Boxed Warning]: The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding.",
"     </b>",
"     Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inherited thrombophilia: Women with inherited thrombophilias (eg, protein C or S deficiency) may have increased risk of venous thromboembolism (DeSancho, 2010; van Vlijmen, 2011). Use is contraindicated in women with hypercoagulopathies (inherited or acquired).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Combination hormonal contraceptives may affect serum triglyceride and lipoprotein levels. Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Progestins may be associated with decreased HDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal bleeding: Unscheduled bleeding/spotting may occur within the first 3 months of combination oral contraceptive use. Presentation of irregular, unresolving vaginal bleeding following previously regular cycles warrants further evaluation including endometrial sampling, if indicated, to rule out malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use caution in patients with asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease.",
"     </b>",
"     Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected. When used for contraception, use with caution in patients with risk factors for cardiovascular disease. May have a dose-related risk of vascular disease and hypertension; women with hypertension should be encouraged to use another form of contraception. Monitor women with well-controlled hypertension and discontinue if blood pressure rises significantly. Use is contraindicated with uncontrolled hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use caution with epilepsy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: Use with caution in patients with gallbladder disease. May have a dose-related risk of gallbladder disease. Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic adenomas: Extremely rare adenomas and focal nodular hyperplasia resulting in fatal intra-abdominal hemorrhage have been reported in association with long-term oral contraceptive use. Presentation of an abdominal mass, acute abdominal pain, or intra-abdominal bleeding warrants further evaluation to rule out source.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic dysfunction: Steroid hormones may be poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur. Use is contraindicated with hepatic disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in women with hereditary angioedema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Use with caution in patients with severe hypocalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use with caution in patients with a history of migraine. Evaluate new, recurrent, severe, or persistent headaches. Use of combination oral contraceptives is contraindicated in women with headaches with focal neurological symptoms or migraine headaches if &gt;35 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Women with renal disease should be encouraged to use a nonhormonal form of contraception.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SLE: Use with caution in patients with SLE.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid replacement therapy: Estrogens may increase thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels. Women on thyroid replacement therapy may require higher doses of thyroid hormone while receiving estrogens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Combination hormonal contraceptives are not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers:",
"     <b>",
"      [U.S. Boxed Warning]: The risk of cardiovascular side effects is increased in women who smoke cigarettes; risk increases with age (especially women &gt;35 years of age) and the number of cigarettes smoked; women who use combination hormonal contraceptives should be strongly advised not to smoke. Use is contraindicated in patients &gt;35 years of age who smoke.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, should be discontinued at least 4-6 weeks prior to and for 2 weeks following elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Safety and efficacy of some products (eg, Generess Fe, Lo Loestrin&trade; Fe) have not been established in women with a BMI &gt;35 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Some products may contain tartrazine, which may cause allergic reactions in certain individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acne use: When used for acne, use only in females &ge;15 years of age, who also desire combination hormonal contraceptive therapy, are unresponsive to topical treatments, have no contraindications to combination hormonal contraceptive use, and plan to stay on therapy for &ge;6 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; HIV infection protection: Combination hormonal contraceptives do not protect against HIV infection or other sexually-transmitted diseases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Minimum effective dosage: Combination hormonal contraceptives: The minimum dosage combination of estrogen/progestin that will effectively treat the individual patient should be used. New patients should be started on products containing &le;0.035 mg of estrogen per tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis use: For use only in women at significant risk of osteoporosis and for who other non-estrogen medications are not considered appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.",
"     </b>",
"     Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied.",
"     <b>",
"      Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F168483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F168435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acitretin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Given the potential for progestin-only preparations to fail to prevent pregnancy during acitretin therapy, such products should not be relied upon. Alternative, nonhormonal forms of contraception must be employed during acitretin therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use of a non-hormone-based contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Progestins). Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Armodafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with armodafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Estrogens) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Progestins) may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Progestins). Management: Administer oral progestin-containing contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with drospirenone. Boceprevir may increase the serum concentration of Contraceptives (Progestins). This has been seen specifically with norethindrone. Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day. Avoid drospirenone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Progestins). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Contraceptives (Progestins). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Norethindrone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May decrease the serum concentration of Norethindrone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Oral Contraceptive (Progestins). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Estrogens). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least one month following the last fosaprepitant/aprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Progestins). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with aprepitant or fosaprepitant and for at least one month following the last aprepitant/fosaprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May increase the metabolism of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use an alternative, nonhormonal form of contraception, or use an alternative to griseofulvin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Contraceptives (Estrogens) may decrease the serum concentration of LamoTRIgine.  Management: Monitor for increased serum concentrations/effects of lamotrigine in patients in whom a hormonal contraceptive is discontinued/dose decreased (this includes during a pill-free week). A reduced dosage of lamotrigine may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May decrease the serum concentration of Contraceptives (Progestins). Management: Women using progestin-only &ldquo;minipill&rdquo; products may be at risk for contraceptive failure; it is unclear if other progestin-containing products would be significantly impacted.  Alternative, non-hormonal, means of contraception are recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Progestins). Mifepristone may increase the serum concentration of Contraceptives (Progestins). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Estrogens). Mifepristone may increase the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Modafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with modafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Estrogens). Average AUC values were unchanged, but there was evidence of substantial patient-to-patient variability in response to this combination. Management: Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Progestins). Management: Use of an additional or alternative (nonhormonal) method of contraception should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Contraceptives (Estrogens). Management: Use of an alternative, nonhormonal form of contraception during nafcillin therapy is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Progestins). Management: Instruct patients receiving nevirapine to use an alternative or additional nonhormonal contraceptive. Nevirapine product labeling however suggests that depo-medroxyprogesterone acetate may be used as a sole method of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Progestins). Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May decrease the serum concentration of Contraceptives (Progestins). Management: Patients should use an alternative, non-hormonal based form of contraception for the duration of concurrent perampanel.  Both oral and non-oral progestin-based contraceptives are likely to be impacted by this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Progestins). Contraceptive failure is possible. Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: May decrease the serum concentration of Norethindrone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Estrogens) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Progestins) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Consider an alternative to St John's wort if possible.  If this combination is used, an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible. Management: Consider using a product other than St John's wort.  Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Progestins). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Contraceptives (Estrogens) may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: Contraceptives (Estrogens) may increase the serum concentration of TiZANidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Progestins). Management: Caution patients that this combination may be associated with reduced contraceptive effectiveness.  Consider adding an additional (non-hormonal) contraceptive method.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Progestins) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Estrogens) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Estrogens) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Progestins) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.  Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Contraceptives (Progestins). Contraceptives (Progestins) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F168463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Routine use increases estrogen level and risk of breast cancer; avoid ethanol. Ethanol may also increase the risk of osteoporosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine. Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well; clinical implications are unclear. Norethindrone absorption is increased by 27% following administration with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, yucca. Herbs with progestogenic properties may enhance the adverse/toxic effect of progestins; examples include bloodroot, chasteberry, damiana, oregano, yucca.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F168438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F168451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy should be ruled out prior to treatment and discontinued if pregnancy occurs. In general, the use of combination hormonal contraceptives when inadvertently taken early in pregnancy have not been associated with teratogenic effects. Hormonal contraceptives may be less effective in obese patients. An increase in oral contraceptive failure was noted in women with a BMI &gt;27.3 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Similar findings were noted in patients weighing &ge;90 kg (198 lb) using the contraceptive patch.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to increased risk of venous thromboembolism (VTE) postpartum, combination hormonal contraceptives should not be started in any woman &lt;21 days following delivery. Women without risk factors for VTE and who are not breast-feeding may start combination hormonal contraceptives during 21-42 days postpartum. After 42 days postpartum, restrictions for use are not related to postpartum status and should be based on other medical conditions (CDC, 2011). May be started immediately following first trimester abortion or miscarriage.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F168477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F168452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Jaundice and breast enlargement in the nursing infant have been reported following the use of combination hormonal contraceptives. May decrease the quality and quantity of breast milk; alternative form of contraception is recommended (per manufacturer). The theoretical concerns about decreased milk production are greatest early in the postpartum period when milk production is being established. Postpartum risk status for VTE should be considered when initiating combination hormonal contraceptives after delivery. Combined hormonal contraceptives should not be started &lt;21 days postpartum due to increased risk of VTE. Risk of VTE is still elevated in breast-feeding women until ~42 days postpartum and is greater in women with additional risk factors. After 42 days postpartum, restrictions for use are not related to postpartum VTE risk and should be based on other medical conditions (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F168453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken at same time each day. May be taken without regard to meals. Ensure adequate calcium and vitamin D intake when used for the prevention of osteoporosis.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F168450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Femcon Fe Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4-35 mg-mcg (28): $92.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Generess FE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.8-25 mg-mcg (28): $86.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Wymzya Fe Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4-35 mg-mcg (28): $73.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Zenchent FE Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4-35 mg-mcg (28): $73.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Aranelle Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5/1/0.5-35 mg-mcg (28): $39.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Balziva Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4-35 mg-mcg (28): $44.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Brevicon (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-35 mg-mcg (28): $74.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cyclafem 1/35 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-35 mg-mcg (28): $31.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cyclafem 7/7/7 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5/0.75/1-35 mg-mcg (28): $33.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Dasetta 1/35 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-35 mg-mcg (28): $29.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Dasetta 7/7/7 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5/0.75/1-35 mg-mcg (28): $32.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Estrostep Fe Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-20/1-30/1-35 mg-mcg (28): $105.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Femhrt Low Dose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-2.5 mg-mcg (28): $83.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Gildagia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4-35 mg-mcg (28): $44.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Gildess 1.5/30 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5-30 mg-mcg (21): $28.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Gildess 1/20 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-20 mg-mcg (21): $28.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Gildess FE 1.5/30 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5-30 mg-mcg (28): $28.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Gildess FE 1/20 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-20 mg-mcg (28): $28.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Jinteli Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-5 mg-mcg (28): $65.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Junel 1.5/30 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5-30 mg-mcg (21): $28.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Junel 1/20 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-20 mg-mcg (21): $28.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Junel FE 1.5/30 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5-30 mg-mcg (28): $28.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Junel FE 1/20 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-20 mg-mcg (28): $28.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Leena Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5/1/0.5-35 mg-mcg (28): $39.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lo Loestrin Fe Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 MG-10 MCG / 10 mcg (28): $92.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Loestrin 1.5/30 (21) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5-30 mg-mcg (21): $45.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Loestrin 1/20 (21) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-20 mg-mcg (21): $45.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Loestrin 24 Fe Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-20 mg-mcg (28): $92.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Loestrin Fe 1.5/30 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5-30 mg-mcg (28): $107.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Loestrin Fe 1/20 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-20 mg-mcg (28): $107.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Microgestin 1.5/30 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5-30 mg-mcg (21): $28.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Microgestin 1/20 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-20 mg-mcg (21): $28.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Microgestin FE 1.5/30 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.5-30 mg-mcg (28): $28.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Microgestin FE 1/20 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-20 mg-mcg (28): $28.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Modicon (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-35 mg-mcg (28): $69.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Necon 0.5/35 (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-35 mg-mcg (28): $32.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Necon 1/35 (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-35 mg-mcg (28): $29.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Necon 10/11 (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     35 mcg (28): $32.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Necon 7/7/7 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5/0.75/1-35 mg-mcg (28): $32.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Norinyl 1+35 (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-35 mg-mcg (28): $74.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nortrel 0.5/35 (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-35 mg-mcg (28): $32.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nortrel 1/35 (21) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-35 mg-mcg (21): $29.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nortrel 1/35 (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-35 mg-mcg (28): $29.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nortrel 7/7/7 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5/0.75/1-35 mg-mcg (28): $32.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ovcon-35 (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4-35 mg-mcg (28): $105.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Philith Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4-35 mg-mcg (28): $44.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tilia Fe Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-20/1-30/1-35 mg-mcg (28): $57.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tri-Legest Fe Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-20/1-30/1-35 mg-mcg (28): $57.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tri-Norinyl (28) Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5/1/0.5-35 mg-mcg (28): $81.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Wera Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-35 mg-mcg (28): $16.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zenchent Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4-35 mg-mcg (28): $44.84",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F168440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before starting therapy, a physical exam with reference to the breasts and pelvis are recommended, including a Papanicolaou smear. Exam may be deferred if appropriate; pregnancy should be ruled out prior to use. Monitor patient closely for loss of vision, sudden onset of proptosis, diplopia, migraine; blood pressure; signs and symptoms of thromboembolic disorders; signs or symptoms of depression; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; thyroid function in patients on thyroid hormone replacement therapy. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Menopausal symptoms: Assess need for therapy at 3- to 6-month intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention of osteoporosis: Bone density measurement",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F168454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Activelle (AR, FI, HK, IL, KP, MY, SE, SG, TH, TW, UY);",
"     </li>",
"     <li>",
"      Brevinor (AU, BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Brevinor 21 (NZ);",
"     </li>",
"     <li>",
"      Brevinor 28 (AU);",
"     </li>",
"     <li>",
"      Covina (TW);",
"     </li>",
"     <li>",
"      Estracomb (IL);",
"     </li>",
"     <li>",
"      Estragest TTS (IL);",
"     </li>",
"     <li>",
"      Eveclin Half (KP);",
"     </li>",
"     <li>",
"      Eveprem (KP);",
"     </li>",
"     <li>",
"      Eviclin (KP);",
"     </li>",
"     <li>",
"      Evorel Cont (IL);",
"     </li>",
"     <li>",
"      Evorel Conti (AR);",
"     </li>",
"     <li>",
"      Evorel Sequi (IL);",
"     </li>",
"     <li>",
"      Evorelconti (MX);",
"     </li>",
"     <li>",
"      Kliogest (KP, PK, SG);",
"     </li>",
"     <li>",
"      Micropil (PH);",
"     </li>",
"     <li>",
"      Norimin (AE, AU, BF, BH, BJ, CI, CY, EG, ET, GB, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NZ, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Novofem (EE, HK);",
"     </li>",
"     <li>",
"      Ortho 7 7 7 (BB, BM, BS, BZ, GY, JM, NL, PR, SR, TT);",
"     </li>",
"     <li>",
"      Ortho-Novum 1 35 (CO, FR);",
"     </li>",
"     <li>",
"      Ortho-Novum 1/35 (FR);",
"     </li>",
"     <li>",
"      Ovysmen (AE, BE, BF, BH, BJ, CI, CY, EG, ET, GB, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Ovysmen 0.5 35 (AT, BE, DE);",
"     </li>",
"     <li>",
"      Ovysmen 1 35 (AT, CH, DE);",
"     </li>",
"     <li>",
"      Synphasic 28 (AU, NZ);",
"     </li>",
"     <li>",
"      Tri-Sequens (KP, SG);",
"     </li>",
"     <li>",
"      Triella (FR);",
"     </li>",
"     <li>",
"      Trinovum (AT, BE, BF, BJ, CH, CI, CO, DE, DK, ET, GB, GH, GM, GN, IE, IT, KE, LR, MA, ML, MR, MU, MW, NE, NG, PL, RU, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Trisekvens (SE);",
"     </li>",
"     <li>",
"      Trisequens (BR, CN, PE, PY, UY);",
"     </li>",
"     <li>",
"      Trisequens Forte (IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F168428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Combination oral contraceptives inhibit ovulation via a negative feedback mechanism on the hypothalamus, which alters the normal pattern of gonadotropin secretion of a follicle-stimulating hormone (FSH) and luteinizing hormone by the anterior pituitary. The follicular phase FSH and midcycle surge of gonadotropins are inhibited. In addition, combination hormonal contraceptives produce alterations in the genital tract, including changes in the cervical mucus, rendering it unfavorable for sperm penetration even if ovulation occurs. Changes in the endometrium may also occur, producing an unfavorable environment for nidation. Combination hormonal contraceptive drugs may alter the tubal transport of the ova through the fallopian tubes. Progestational agents may also alter sperm fertility.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     In postmenopausal women, exogenous estrogen is used to replace decreased endogenous production. The addition of progestin reduces the incidence of endometrial hyperplasia and risk of endometrial cancer in women with an intact uterus.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F168446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Norethindrone: See individual monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethinyl estradiol:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bioavailability: 43% to 55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2-4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protein binding: &gt;95% to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Hepatic via oxidation and conjugation in GI tract; hydroxylated via CYP3A4 to metabolites; first-pass effect; enterohepatic recirculation; reversibly converted to estrone and estriol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life elimination: 19-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excretion: Urine (as estradiol, estrone, and estriol); feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al, \"Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,\"",
"      <i>",
"       Lancet Oncol,",
"      </i>",
"      2012,13(5):476-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/43/32442/abstract-text/22401913/pubmed\" id=\"22401913\" target=\"_blank\">",
"        22401913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Limacher M, Assaf AR, et al, \"Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/43/32442/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burkman R, Schlesselman JJ, and Zieman M, &ldquo;Safety Concerns and Health Benefits Associated With Oral Contraception,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2004, 190(4 Suppl):5-22.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(26):878-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/43/32442/abstract-text/21734635/pubmed\" id=\"21734635\" target=\"_blank\">",
"        21734635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al, \"Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(6):573-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/43/32442/abstract-text/19196674/pubmed\" id=\"19196674\" target=\"_blank\">",
"        19196674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSancho MT, Dorff T, and Rand JH, \"Thrombophilia and the Risk of Thromboembolic Events In Women on Oral Contraceptives and Hormone Replacement Therapy,\"",
"      <i>",
"       Blood Coagul Fibrinolysis",
"      </i>",
"      , 2010, 21(6):534-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/43/32442/abstract-text/20581664/pubmed\" id=\"20581664\" target=\"_blank\">",
"        20581664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsia J, Langer RD, Manson JE, et al, \"Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/43/32442/abstract-text/16476878/pubmed\" id=\"16476878\" target=\"_blank\">",
"        16476878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holt VL, Scholes D, Wicklund KG, et al, &ldquo;Body Mass Index, Weight, and Oral Contraceptive Failure Risk,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2005, 105(1):46-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/43/32442/abstract-text/15625141/pubmed\" id=\"15625141\" target=\"_blank\">",
"        15625141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(3):298-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/43/32442/abstract-text/19602689/pubmed\" id=\"19602689\" target=\"_blank\">",
"        19602689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society [NAMS], \"The 2012 Hormone Therapy Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(3):257-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/43/32442/abstract-text/22367731/pubmed\" id=\"22367731\" target=\"_blank\">",
"        22367731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orme ML, Back DJ, and Breckenridge AM, &ldquo;Clinical Pharmacokinetics of Oral Contraceptive Steroids,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1983, 8(2):95-136.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/43/32442/abstract-text/6342899/pubmed\" id=\"6342899\" target=\"_blank\">",
"        6342899",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/43/32442/abstract-text/12117397/pubmed\" id=\"12117397\" target=\"_blank\">",
"        12117397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shenfield GM and Griffin JM, &ldquo;Clinical Pharmacokinetics of Contraceptive Steroids. An Update,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1991, 20(1):15-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/43/32442/abstract-text/2029800/pubmed\" id=\"2029800\" target=\"_blank\">",
"        2029800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(20):2651-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/43/32442/abstract-text/12771112/pubmed\" id=\"12771112\" target=\"_blank\">",
"        12771112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitruk-Ware R and Nath A, \"Metabolic Effects of Contraceptive Steroids,\"",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2011, 12(2):63-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/43/32442/abstract-text/21538049/pubmed\" id=\"21538049\" target=\"_blank\">",
"        21538049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, Department of Health and Human Services, &ldquo;WHIMS Study on Estrogen/Progestin,&rdquo; May 27, 2003. Available at",
"      <a href=\"file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm\" target=\"_blank\">",
"       file://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al, \"Thrombotic Risk During Oral Contraceptive Use and Pregnancy in Women With Factor V Leiden or Prothrombin Mutation: A Rational Approach to Contraception,\"",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(8):2055-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/43/32442/abstract-text/21659542/pubmed\" id=\"21659542\" target=\"_blank\">",
"        21659542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9436 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-0E8BE10A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32442=[""].join("\n");
var outline_f31_43_32442=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708765\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168468\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168469\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168488\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168472\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168482\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3182139\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168473\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168474\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168442\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168425\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168444\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168443\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168485\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168496\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168486\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168447\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168429\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168483\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168435\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168463\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168438\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168451\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168477\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168452\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168453\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168450\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168440\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168454\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168428\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168446\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9436\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9436|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/19/311?source=related_link\">",
"      Ethinyl estradiol and norethindrone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_43_32443="Carpal ossification";
var content_f31_43_32443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ossification centers and epiphyseal growth plate maturation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Bone",
"       </td>",
"       <td class=\"subtitle1\">",
"        Appearance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Closure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capitate",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"       <td>",
"        13 to 15 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hamate",
"       </td>",
"       <td>",
"        3 to 4 months",
"       </td>",
"       <td>",
"        13 to 15 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radius",
"       </td>",
"       <td>",
"        10 to 12 montsh",
"       </td>",
"       <td>",
"        16 to 17 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triquetrum",
"       </td>",
"       <td>",
"        2 to 3 years",
"       </td>",
"       <td>",
"        13 to 15 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lunate",
"       </td>",
"       <td>",
"        3 years",
"       </td>",
"       <td>",
"        13 to 16 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scaphoid",
"       </td>",
"       <td>",
"        4 to 5 years",
"       </td>",
"       <td>",
"        13 to 16 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trapezium",
"       </td>",
"       <td>",
"        4 to 6 years",
"       </td>",
"       <td>",
"        13 to 16 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trapezoid",
"       </td>",
"       <td>",
"        4 to 6 years",
"       </td>",
"       <td>",
"        13 to 16 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulna",
"       </td>",
"       <td>",
"        6 years",
"       </td>",
"       <td>",
"        15 to 17 years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32443=[""].join("\n");
var outline_f31_43_32443=null;
var title_f31_43_32444="UNOS priority status for HT";
var content_f31_43_32444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83792&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    UNOS priority status for heart transplant",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Status 1A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          Reside in the transplant listing center and at least one of the following:",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp; On mechanical ventilation",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -&nbsp; On intraaortic balloon pump, total artificial heart, or&nbsp;extracorporeal&nbsp;membrane oxygentator",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp; Hemodynamic monitoring with single high-dose intravenous inotrope or multiple intravenous inotropes (eg, dobutamine &gt;7.5 mcg/kg/min plus milrinone 0.5 mcg/kg/min)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          &nbsp;For 30 days after implantation with a left and/or right ventricular assist device for acute decompensation (need not be admitted to the listing center)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          &nbsp; A candidate with a total artificial heart who has been discharged from the listing center may be listed as Status 1A for 30 days after the discharge. (This provision will expire on December 1, 2012.)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          LVAD with a device-related complication (such as thromboembolism, device infection, mechanical failure, or life-threatening ventricular arrhythmias)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Status 1B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          Infusion of intravenous inotropes or&nbsp;supported by an implanted chronic (left&nbsp;and/or right)&nbsp;mechanical assist device",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <ul>",
"         <li>",
"          &nbsp;A candidate with a total artificial heart who has been discharged from the listing hospital may be listed as Status 1B at ay point in time after discharge.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Status 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All candidates who do not meet 1A or 1B requirements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Status 7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Temporarily unsuitable to receive a thoracic organ transplant.&nbsp;During the inactive period there is no gain or loss of&nbsp;accrued time.",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based on guidelines from: Organ Procurement and Transplantation Network (OPTN). Organ Distribution: Allocation of Thoracic Organs. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, November 15, 2011. file://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp (Accessed on May 31, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32444=[""].join("\n");
var outline_f31_43_32444=null;
var title_f31_43_32445="Activation of leflunomide";
var content_f31_43_32445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Activation of leflunomide",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 326px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Leflunomide is converted into its active metabolite A77 1726.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Fox RI, J Rheumatol 1998; 25:20.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32445=[""].join("\n");
var outline_f31_43_32445=null;
var title_f31_43_32446="Rapid overview for hypoglycemia in children";
var content_f31_43_32446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapid overview for hypoglycemia in adolescents and children, other than neonates",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Any",
"        </strong>",
"        patient with acute lethargy or coma should have an immediate measurement of blood glucose to determine if hypoglycemia is a possible cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other findings of hypoglycemia are nonspecific* and vary by age:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <ul>",
"         <li>",
"          <strong>",
"           Infants",
"          </strong>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Irritability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Lethargy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Jitteriness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Feeding problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Hypothermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Hypotonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Tachypnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Cyanosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Apnea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <ul>",
"         <li>",
"          <strong>",
"           Older children and adolescents",
"          </strong>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4_start\">",
"        - Autonomic response (tends to occur with blood glucose &lt;50 to 65 mg/dL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Sweating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Palpitations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Tremor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Nervousness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Hunger",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Paresthesias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Pallor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4_start\">",
"        - Neuroglycopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Irritability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Confusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Uncharacteristic behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Coma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Occasionally, transient focal neurologic deficits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <ul>",
"         <li>",
"          Obtain rapid bedside blood glucose concentration",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <ul>",
"         <li>",
"          Confirm the presence of hypoglycemia with a simultaneously drawn plasma glucose",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <ul>",
"         <li>",
"          Treat, as outlined below, if the bedside value is low (&lt;70 mg/dL [3.89 mmol/L]) in symptomatic patients",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <ul>",
"         <li>",
"          Obtain a blood sample for additional diagnostic studies prior to glucose administration, if possible, and collect the first voided urine after the hypoglycemic event in all infants and young children who are not being treated for diabetes mellitus or do not have a known cause for hypoglycemia",
"          <sup>",
"           &Delta;",
"          </sup>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <ul>",
"         <li>",
"          <strong>",
"           Do not delay",
"          </strong>",
"          treatment if symptomatic hypoglycemia is suspected. However, every reasonable effort should be made to obtain a rapid blood glucose measurement",
"          <strong>",
"           prior",
"          </strong>",
"          to administering glucose.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <ul>",
"         <li>",
"          <strong>",
"           Give glucose based upon the patients level of consciousness and ability to swallow safely (ie, alert enough to do so and with intact gag reflex) as follows:",
"          </strong>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4_start\">",
"        <strong>",
"         Conscious and able to drink and swallow safely:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Administer 0.3 grams/kg (10 to 20 grams) of a rapidly-absorbed carbohydrate (eg, 2 to 3 glucose tablets, a tube of gel with 15 grams, 4 oz (120 mL) sweetened fruit juice, non-diet soda, or a teaspoon (5 mL) of honey or table sugar. May repeat in 10 to 15 minutes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4_start\">",
"        <strong>",
"         Altered mental status, unable to swallow, or does not respond to oral glucose administration within 15 minutes:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Give an initial IV bolus of glucose of 0.25 grams/kg of dextrose (maximum single dose 25 grams).",
"        <sup>",
"         &loz;",
"        </sup>",
"        The volume and concentration of glucose bolus is infused slowly at 2 to 3 mL per minute and based upon age:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist6\">",
"        2.5 mL/kg of 10 percent dextrose solution (D10W) in infants and children up to 12 years of age (10 percent dextrose is 100 mg/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist6\">",
"        1 mL/kg of 25 percent dextrose (D25W) or 0.5 mL/kg of 50 percent dextrose (D50W) in adolescents (25 percent dextrose is 250 mg/mL; 50 percent dextrose is 500 mg/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4_start\">",
"        <strong>",
"         Unable to receive oral glucose and unable to obtain IV access:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist4\">",
"        Give glucagon 0.03 mg/kg IM or SQ (maximum dose 1 mg)",
"        <sup>",
"         &sect;",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist6\">",
"        Perform blood glucose monitoring every 10 to 15 minutes as the effects of glucagon may be transient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist6\">",
"        Establish vascular access as soon as possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <ul>",
"         <li>",
"          After initial hypoglycemia is reversed, provide additional glucose and treatment based upon suspected etiology:",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Give children and adolescents with type I diabetes mellitus a normal diet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Give patients with an unknown cause of hypoglycemia intravenous infusion of dextrose 10 percent (6 to 9 mg/kg per minute) titrated to maintain blood glucose in a safe and appropriate range (70 to 150 mg/dL [3.89 to 8.33 mmol/L])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Give patients, who have ingested a sulfonylurea and have recurrent hypoglycemia, octreotide (dose: 1 to 1.5 mcg/kg IM or SQ, maximum dose 150 mcg every 6 hours) in addition to glucose. (Refer to UpToDate topic on sulfonylurea poisoning).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <ul>",
"         <li>",
"          Measure a rapid blood and plasma glucose 15 to 30 minutes after the initial IV glucose bolus and then monitor every 30 to 60 minutes until stable (minimum of four hours) to ensure that plasma glucose concentration is maintained in the normal range (&gt;70 to 100 mg/dL [&gt;3.89 to 5.55 mmol/L])",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <ul>",
"         <li>",
"          Obtain pediatric endocrinology consultation for patients with hypoglycemia of unknown cause",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <ul>",
"         <li>",
"          Obtain medical toxicology consultation for patients with ingestion of oral hypoglycemic agents by calling the United States Poison Control Network at 1-800-222-1222 or access the World Health Organization&rsquo;s list of international poison centers (www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other_start\">",
"        <ul>",
"         <li>",
"          Admit the following patients:",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Cannot maintain normoglycemia with oral intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Hypoglycemia of unknown cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Ingestion of long-acting hypoglycemic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        - Recurrent hypoglycemia during the period of observation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenous; IM: intramuscular; SQ: subcutaneous; D10W: 10 percent dextrose in water; D25W: 25 percent dextrose in water; D50W: 50 percent dextrose in water.",
"     <br>",
"      * These findings may also occur in infants with sepsis, congenital heart disease, respiratory distress syndrome, intraventricular hemorrhage, other metabolic disorders, and in children and adolescents with a variety of underlying conditions.",
"      <br>",
"       &Delta; Specific laboratory studies to obtain in children include blood samples for glucose, insulin, C-peptide, beta-hydroxybutyrate, lactate (free flowing blood must be obtained without a tourniquet), plasma acylcarnitines, free fatty acids, growth hormone, and cortisol.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Higher doses of glucose (eg, 0.5 to 1 g/kg [5 to 10 mL/kg of 10 percent dextrose in water OR 2 to 4 mL/kg of 25 percent dextrose in water]) may be needed to correct hypoglycemia caused by sulfonylurea ingestion. (For more detail, refer to UpToDate topic on sulfonylurea agent poisoning).",
"        <br>",
"         &sect; Glucagon will reverse hypoglycemia caused by excess endogenous or exogenous insulin and will not be effective in patients with inadequate glycogen stores (prolonged fasting), ketotic hypoglycemia, or are unable to mobilize glycogen (glycogen storage diseases). Of note, children may exhaust their glycogen stores in as little as 12 hours. Other conditions in which glycogen cannot be effectively mobilized include ethanol intoxication in children, adrenal insufficiency, and certain inborn errors of metabolism (eg, a disorder of glycogen synthesis and glycogen storage diseases).",
"         <br/>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32446=[""].join("\n");
var outline_f31_43_32446=null;
var title_f31_43_32447="Obstructive emphysema B";
var content_f31_43_32447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Obstructive emphysema in a child following foreign body aspiration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal inspiratory chest X-ray in a child following right-sided foreign body aspiration&nbsp;(top). Obstructive emphysema is noted during expiration only (bottom).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_43_32447=[""].join("\n");
var outline_f31_43_32447=null;
               